Immune    O
regulating    O
proteins    O
found    O
in    O
prostasomes    O
include    O
:    O
amino    O
-    O
peptidase    O
N    O
(    O
CD13    O
)    O
;    O
dipeptidyl    O
-    O
peptidase    O
IV    O
(    O
CD26    O
)    O
;    O
enkephalinase    O
(    O
neutral    O
endopeptidase    O
,    O
CD10    O
)    O
;    O
angiotensin    O
converting    O
enzyme    O
(    O
ACE    O
,    O
CD143    O
)    O
;    O
tissue    O
factor    O
TF    O
(    O
CD142    O
,    O
thromboplastin    O
)    O
;    O
decay    O
accelerating    O
factor    O
(    O
CD55    B-Assay100791527
)    O
;    O
protectin    O
(    O
CD59    O
,    O
inhibitor    O
of    O
MAC    O
)    O
and    O
complement    O
regulatory    O
membrane    O
cofactor    O
protein    O
(    O
CD46    O
)    O
.    O

Of    O
note    O
,    O
the    O
FLAER    O
-    O
based    O
assay    O
is    O
not    O
suitable    O
for    O
evaluation    O
of    O
erythrocytes    O
and    O
platelets    O
in    O
PNH    O
but    O
flow    O
cytometry    O
assays    O
based    O
on    O
CD55    B-Assay100791527
,    O
CD59    O
and    O
others    O
are    O
suitable    O
.    O

Complement    O
Receptor    O
1    O
(    O
CR1    O
or    O
CD35    O
)    O
and    O
DAF    O
(    O
decay    B-Assay100791527
accelerating    I-Assay100791527
factor    I-Assay100791527
also    O
known    O
as    O
CD55    B-Assay100791527
)    O
compete    O
with    O
Factor    O
B    O
in    O
binding    O
with    O
C3b    O
on    O
the    O
cell    O
surface    O
and    O
can    O
even    O
remove    O
Bb    O
from    O
an    O
already    O
formed    O
C3bBb    O
complex    O

Mutations    O
affecting    O
GPI    O
that    O
reduce    O
expression    O
of    O
CD59    O
and    O
decay-accelerating    B-Assay100791527
factor    I-Assay100791527
on    O
red    O
blood    O
cells    O
result    O
in    O
paroxysmal    O
nocturnal    O
hemoglobinuria    O
.    O

When    O
the    O
cause    O
is    O
not    O
obvious    O
,    O
clinicians    O
use    O
other    O
tests    O
,    O
such    O
as    O
:    O
ESR    O
,    O
ferritin    O
,    O
serum    B-Assay100791527
iron    I-Assay100791527
,    O
transferrin    O
,    O
RBC    O
folate    O
level    O
,    O
serum    O
vitamin    O
B12    O
,    O
hemoglobin    B-Assay100791527
electrophoresis    I-Assay100791527
,    O
renal    O
function    O
tests    O
(    O
e.g.    O
serum    O
creatinine    O
)    O
although    O
the    O
tests    O
will    O
depend    O
on    O
the    O
clinical    O
hypothesis    O
that    O
is    O
being    O
investigated    O
.    O

A    O
simple    O
approximation    O
is    O
T3/T4    O
ratio    O
,    O
a    O
more    O
elaborate    O
approach    O
is    O
calculating    O
sum    B-Assay100791527
activity    I-Assay100791527
of    I-Assay100791527
peripheral    I-Assay100791527
deiodinases    I-Assay100791527
(    O
GD    O
)    O
from    O
free    O
T4    O
,    O
free    O
T3    O
and    O
parameters    O
for    O
protein    O
binding    O
,    O
dissociation    O
and    O
hormone    O
kinetics    O
.    O

Dalrymple    O
is    O
remembered    O
for    O
his    O
histological    O
work    O
done    O
with    O
Henry    O
Bence    O
Jones    O
(    O
1814    O
-    O
1873    O
)    O
in    O
the    O
discovery    O
of    O
the    O
albumin    O
that    O
was    O
to    O
become    O
known    O
as    O
Bence    B-Assay100791527
Jones    I-Assay100791527
protein    I-Assay100791527
.    O

Light    O
chains    O
only    O
(    O
or    O
Bence    B-Assay100791527
Jones    I-Assay100791527
protein    I-Assay100791527
)    O
.    O

A    O
major    O
advance    O
in    O
these    O
structural    O
studies    O
was    O
the    O
discovery    O
in    O
the    O
early    O
1960s    O
by    O
Gerald    O
Edelman    O
and    O
Joseph    O
Gally    O
of    O
the    O
antibody    O
light    O
chain    O
,    O
and    O
their    O
realization    O
that    O
this    O
protein    O
is    O
the    O
same    O
as    O
the    O
Bence-Jones    B-Assay100791527
protein    I-Assay100791527
described    O
in    O
1845    O
by    O
Henry    O
Bence    O
Jones    O
.    O

---    O
latex    B-Assay100791527
fixation    I-Assay100791527
tests    I-Assay100791527

A    O
presumptive    O
diagnosis    O
can    O
be    O
made    O
based    O
in    O
the    O
history    O
and    O
clinical    O
signs    O
,    O
but    O
definitive    O
diagnosis    O
requires    O
bacterial    O
culture    O
and    O
serological    O
testing    O
such    O
as    O
ELISA    O
and    O
latex    B-Assay100791527
agglutination    I-Assay100791527
.    O

In    O
this    O
respect    O
,    O
the    O
naming    O
of    O
the    O
rules    O
is    O
similar    O
to    O
that    O
of    O
the    O
Bristol    B-Assay100791527
stool    I-Assay100791527
scale    I-Assay100791527
or    O
the    O
Glasgow    O
Coma    O
Scale    O
(    O
GCS    O
)    O
,    O
which    O
also    O
take    O
their    O
names    O
from    O
the    O
cities    O
in    O
which    O
they    O
were    O
formulated    O
.    O

Bristol    B-Assay100791527
stool    I-Assay100791527
chart    I-Assay100791527
,    O
an    O
medical    O
assessment    O
scale    O
for    O
feces    O

Increased    O
mean    B-Assay100791527
corpuscular    I-Assay100791527
volume    I-Assay100791527
(    O
MCV    O
,    O
>    O
100    O
fL    O
)    O
and    O
mean    B-Assay100791527
corpuscular    I-Assay100791527
hemoglobin    I-Assay100791527
(    O
MCH    O
)    O

|rowspan=2|    O
Mean    B-Assay100791527
cell    I-Assay100791527
hemoglobin    I-Assay100791527
(    O
MCH    O
)    O

Romanowsky    B-Assay100791527
stain    I-Assay100791527

The    O
granules    O
of    O
the    O
mast    O
cell    O
stain    O
blue    O
to    O
dark    O
purple    O
with    O
a    O
Romanowsky    B-Assay100791527
stain    I-Assay100791527
,    O
and    O
the    O
cells    O
are    O
medium    O
-    O
sized    O
.    O

Dmitri    O
Leonidovich    O
Romanowsky    O
(    O
sometimes    O
spelled    O
Dmitry    O
and    O
Romanowski    O
,    O
;    O
1861–1921    O
)    O
was    O
a    O
Russian    O
physician    O
who    O
is    O
best    O
known    O
for    O
his    O
invention    O
of    O
an    O
eponymous    O
histological    O
stain    O
called    O
Romanowsky    B-Assay100791527
stain    I-Assay100791527
.    O

1904    O
Nocht    O
's    O
assistant    O
,    O
chemist    O
Gustav    O
Giemsa    O
creates    O
the    O
Giemsa    O
stain    O
,    O
an    O
improvement    O
of    O
the    O
existing    O
Romanowsky    B-Assay100791527
stain    I-Assay100791527
.    O

Frei    B-Assay100791527
test    I-Assay100791527
,    O
a    O
test    O
developed    O
in    O
1925    O
by    O
Wilhelm    O
Siegmund    O
Frei    O
,    O
a    O
German    O
dermatologist    O
,    O
to    O
identify    O
lymphogranuloma    O
inguinale    O

The    O
assay    O
is    O
performed    O
using    O
dried    O
blood    O
from    O
a    O
Guthrie    B-Assay100791527
card    I-Assay100791527
,    O
from    O
which    O
DNA    O
is    O
extracted    O
.    O

Schick    B-Assay100791527
test    I-Assay100791527
–    O
Béla    O
Schick    O

A    O
few    O
substances    O
are    O
below    O
this    O
main    O
interval    O
,    O
e.g.    O
thyroid    O
stimulating    O
hormone    O
,    O
being    O
measured    O
in    O
m    O
,    O
or    O
above    O
,    O
like    O
rheumatoid    O
factor    O
and    O
CA19-9    B-Assay100791527
,    O
being    O
measured    O
in    O
U    O
/    O
mL.    O

A    O
CA    B-Assay100791527
19-9    I-Assay100791527
level    O
may    O
be    O
taken    O
to    O
investigate    O
for    O
cholangiocarcinoma    O
.    O

Cholangiocarcinoma    O
can    O
be    O
detected    O
with    O
these    O
commonly    O
used    O
tumor    O
markers    O
:    O
carbohydrate    B-Assay100791527
antigen    I-Assay100791527
19-9    I-Assay100791527
(    O
CA    O
19    O
-    O
9    O
)    O
,    O
carcinoembryonic    O
antigen    O
(    O
CEA    O
)    O
and    O
cancer    O
antigen    O
125    O
(    O
CA125    O
)    O
.    O

Typhidot    B-Assay100791527
is    O
the    O
other    O
test    O
used    O
to    O
ascertain    O
the    O
diagnosis    O
of    O
typhoid    O
fever    O
.    O

FN3    O
K    O
catalyzes    O
phosphorylation    O
of    O
fructosamine    B-Assay100791527
formed    O
by    O
glycation    O
,    O
the    O
nonenzymatic    O
reaction    O
of    O
glucose    O
with    O
primary    O
amines    O
followed    O
by    O
Amadori    O
rearrangement    O
.    O

There    O
is    O
some    O
data    O
suggesting    O
that    O
1,5-AG    O
values    O
are    O
useful    O
to    O
fill    O
the    O
gap    O
and    O
offer    O
complementary    O
information    O
to    O
HbA1c    O
and    O
fructosamine    B-Assay100791527
tests    O
.    O

Sweat    B-Assay100791527
testing    I-Assay100791527
is    O
more    O
likely    O
to    O
be    O
equivocal    O
in    O
infants    O
and    O
typically    O
not    O
attempted    O
in    O
those    O
under    O
5    O
kg    O
.    O

If    O
sweat    B-Assay100791527
test    I-Assay100791527
is    O
positive    O
more    O
expansive    O
gene    O
testing    O
is    O
considered    O
.    O

suPARnostic    B-Assay100791527
is    O
a    O
prognostic    O
test    O
used    O
to    O
detect    O
suPAR    O
levels    O
in    O
blood    O
plasma    O
.    O

Fluorescein-labeled    B-Assay100791527
proaerolysin    I-Assay100791527
(    O
FLAER    O
)    O
is    O
used    O
in    O
a    O
flow    O
cytometric    O
assay    O
to    O
diagnose    O
paroxysmal    O
nocturnal    O
hemoglobinuria    O
(    O
PNH    O
)    O
.    O

A    O
coagulation    B-Assay100791527
screen    I-Assay100791527
is    O
a    O
combination    O
of    O
screening    O
laboratory    O
tests    O
,    O
designed    O
to    O
provide    O
rapid    O
non    O
-    O
specific    O
information    O
,    O
which    O
allows    O
an    O
initial    O
broad    O
categorization    O
of    O
haemostatic    O
problems    O
.    O

Vertical    B-Assay100791527
auto    I-Assay100791527
profile    I-Assay100791527
,    O
cholesterol    O
,    O
lipid    O
and    O
lipoprotein    O
blood    O
test    O

Biorheological    O
analyses    O
include    O
study    O
of    O
pathological    O
processes    O
through    O
clinical    O
research    O
in    O
the    O
related    O
fields    O
of    O
hemodynamics    O
and    O
hemorheology    B-Assay100791527
,    O
and    O
may    O
have    O
clinical    O
implications    O
in    O
aiding    O
the    O
treatment    O
of    O
specific    O
diseases    O
.    O

Hemorheology    B-Assay100791527
,    O
the    O
study    O
of    O
flow    O
properties    O
of    O
blood    O
and    O
its    O
elements    O
.    O

The    O
study    O
of    O
the    O
properties    O
of    O
the    O
blood    O
flow    O
is    O
called    O
hemorheology    B-Assay100791527
.    O

|    O
Viscosity    B-Assay100791527

Aaron    O
Bodansky    O
(    O
1887    O
,    O
Elizabethgrad    O
-    O
1960    O
)    O
was    O
a    O
Russian    O
-    O
born    O
American    O
biochemist    O
remembered    O
for    O
describing    O
the    O
Bodansky    B-Assay100791527
unit    I-Assay100791527
in    O
the    O
measurement    O
of    O
alkaline    O
phosphatase    O
in    O
blood    O
.    O

Paraprotein    B-Assay100791527

Those    O
with    O
myeloma    O
will    O
typically    O
display    O
a    O
rouleaux    O
formation    O
on    O
a    O
peripheral    O
smear    O
and    O
a    O
large    O
globulin    O
gap    O
,    O
indicative    O
of    O
a    O
significant    O
paraprotein    B-Assay100791527
load    O
.    O

Paraproteinemia    O
,    O
also    O
known    O
as    O
monoclonal    O
gammopathy    O
,    O
is    O
the    O
presence    O
of    O
excessive    O
amounts    O
of    O
paraprotein    B-Assay100791527
or    O
single    O
monoclonal    O
gammaglobulin    O
in    O
the    O
blood    O
.    O

a    O
paraprotein    B-Assay100791527
in    O
the    O
blood    O
(    O
an    O
MGUS    O
in    O
approximately    O
80%    O
of    O
cases    O
)    O
.    O

Sabin–Feldman    B-Assay100791527
dye    I-Assay100791527
test    I-Assay100791527
,    O
a    O
serologic    O
test    O
to    O
diagnose    O
for    O
toxoplasmosis    O

Neurosecretion    O
cells    O
also    O
release    O
their    O
product    O
farther    O
than    O
normal    O
neurons    O
,    O
which    O
only    O
secrete    O
short    O
distances    O
,    O
into    O
the    O
extracellular    O
space    O
some    O
distance    O
from    O
the    O
target    B-Assay100791527
cell    I-Assay100791527
.    O

Basophilic    O
stippling    O
is    O
marked    O
and    O
target    B-Assay100791527
cells    I-Assay100791527
are    O
common    O
.    O

---    O
counterimmunoelectrophoresis    B-Assay100791527

Because    O
macrocytosis    O
usually    O
precedes    O
a    O
low    O
platelet    O
count    O
,    O
patients    O
with    O
typical    O
congenital    O
anomalies    O
associated    O
with    O
FA    O
should    O
be    O
evaluated    O
for    O
an    O
elevated    O
red    O
blood    O
cell    O
mean    B-Assay100791527
corpuscular    I-Assay100791527
volume    I-Assay100791527
.    O

Increased    O
mean    B-Assay100791527
corpuscular    I-Assay100791527
volume    I-Assay100791527
(    O
MCV    O
,    O
>    O
100    O
fL    O
)    O
and    O
mean    B-Assay100791527
corpuscular    I-Assay100791527
hemoglobin    I-Assay100791527
(    O
MCH    O
)    O

|rowspan=2|    O
Mean    B-Assay100791527
cell    I-Assay100791527
volume    I-Assay100791527
(    O
MCV    O
)    O

The    O
mean    B-Assay100791527
cell    I-Assay100791527
volume    I-Assay100791527
is    O
commonly    O
decreased    O
(    O
i.e.    O
,    O
a    O
microcytic    O
anemia    O
)    O
,    O
but    O
MCV    O
may    O
also    O
be    O
normal    O
or    O
even    O
high    O
.    O

The    O
mean    B-Assay100791527
corpuscular    I-Assay100791527
volume    I-Assay100791527
or    O
MCV    O
is    O
usually    O
normal    O
or    O
low    O
for    O
congenital    O
causes    O
of    O
sideroblastic    O
anemia    O
but    O
normal    O
or    O
high    O
for    O
acquired    O
forms    O
.    O

Other    O
tests    O
for    O
detecting    O
amniotic    O
fluid    O
mainly    O
include    O
nitrazine    B-Assay100791527
paper    O
test    O
and    O
fern    O
test    O
.    O

The    O
Abelin    B-Assay100791527
reaction    I-Assay100791527
is    O
a    O
qualitative    O
reaction    O
for    O
demonstrating    O
the    O
presence    O
of    O
arsphenamine    O
and    O
neoarsphenamine    O
in    O
blood    O
and    O
urine    O
.    O

Poikilocytosis    B-Assay100791527

Microscopic    O
viewing    O
of    O
the    O
red    O
blood    O
cells    O
will    O
reveal    O
marked    O
unequal    B-Assay100791527
cell    I-Assay100791527
size    I-Assay100791527
and    O
abnormal    B-Assay100791527
cell    I-Assay100791527
shape    I-Assay100791527
.    O

Tetramer    B-Assay100791527
assay    I-Assay100791527
detect    O
the    O
presence    O
of    O
antigen    O
specific    O
T    O
-    O
cells    O

|    O
Serum    B-Assay100791527
total    I-Assay100791527
protein    I-Assay100791527

Triple    B-Assay100791527
bolus    I-Assay100791527
test    I-Assay100791527

U&E    O
–    O
Urea    O
and    O
electrolytes    O
,    O
see    O
also    O
Basic    B-Assay100791527
metabolic    I-Assay100791527
panel    I-Assay100791527

A    O
basic    B-Assay100791527
metabolic    I-Assay100791527
panel    I-Assay100791527
(    O
BMP    B-Assay100791527
)    O
is    O
a    O
blood    O
test    O
consisting    O
of    O
a    O
set    O
of    O
seven    O
or    O
eight    O
biochemical    O
tests    O
and    O
is    O
one    O
of    O
the    O
most    O
common    O
lab    O
tests    O
ordered    O
by    O
health    O
care    O
providers    O
.    O

Outside    O
the    O
United    O
States    O
,    O
blood    O
tests    O
made    O
up    O
of    O
the    O
majority    O
of    O
the    O
same    O
biochemical    O
tests    O
are    O
called    O
urea    B-Assay100791527
and    I-Assay100791527
electrolytes    I-Assay100791527
(    O
U&E    B-Assay100791527
or    O
"    O
Us    B-Assay100791527
and    I-Assay100791527
Es    I-Assay100791527
"    O
)    O
,    O
or    O
urea,    B-Assay100791527
electrolytes,    I-Assay100791527
creatinine    I-Assay100791527
(    O
UEC    B-Assay100791527
or    O
EUC    B-Assay100791527
or    O
CUE    B-Assay100791527
)    O
,    O
and    O
are    O
often    O
referred    O
to    O
as    O
'    O
kidney    O
function    O
tests    O
'    O
as    O
they    O
also    O
include    O
a    O
calculated    O
estimated    O
glomerular    O
filtration    O
rate    O
.    O

Other    O
side    O
effects    O
of    O
osaterone    O
acetate    O
include    O
diminished    O
sperm    O
quality    O
(    O
for    O
up    O
to    O
6    O
weeks    O
post    O
-    O
treatment    O
)    O
,    O
transient    O
elevation    O
of    O
liver    B-Assay100791527
enzyme    I-Assay100791527
(    O
caution    O
should    O
be    O
observed    O
with    O
known    O
liver    O
disease    O
)    O
,    O
vomiting    O
,    O
diarrhea    O
,    O
polyuria    O
/    O
polydipsia    O
,    O
lethargy    O
,    O
and    O
hyperplasia    O
of    O
the    O
mammary    O
glands    O
.    O

Ultrasound    O
of    O
the    O
abdomen    O
and    O
blood    O
tests    O
evaluating    O
liver    B-Assay100791527
function    I-Assay100791527
are    O
often    O
performed    O
to    O
rule    O
out    O
metastasis    O
to    O
the    O
liver    O
.    O

Abnormal    O
results    O
of    O
liver    B-Assay100791527
function    I-Assay100791527
studies    I-Assay100791527

Lab    O
studies    O
that    O
should    O
be    O
ordered    O
include    O
a    O
complete    O
blood    O
count    O
,    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
and    O
lipase    O
.    O

Serious    O
side    O
effects    O
can    O
include    O
liver    O
problems    O
and    O
regular    O
monitoring    O
of    O
liver    B-Assay100791527
function    I-Assay100791527
test    I-Assay100791527
is    O
therefore    O
recommended    O
.    O

The    O
presentation    O
in    O
childhood    O
may    O
be    O
asymptomatic    O
or    O
with    O
elevated    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
.    O

liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
to    O
exclude    O
liver    O
disease    O
as    O
a    O
cause    O
of    O
coagulation    O
factor    O
deficiency    O

People    O
undergoing    O
systemic    O
treatment    O
must    O
have    O
regular    O
blood    O
and    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
to    O
check    O
for    O
medication    O
toxicities    O
.    O

liver    B-Assay100791527
enzyme    I-Assay100791527
abnormalities    O
(    O
increased    O
ALT    O
and    O
AST    O
)    O

Enzyme    O
activity    O
(    O
kat    O
)    O
is    O
commonly    O
used    O
for    O
e.g.    O
liver    B-Assay100791527
function    I-Assay100791527
test    I-Assay100791527
like    O
AST    O
,    O
ALT    O
,    O
LD    O
and    O
γ-GT    O
in    O
Sweden    O
.    O

The    O
serum    O
albumin    O
level    O
is    O
part    O
of    O
a    O
standard    O
panel    O
of    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
.    O

Before    O
this    O
procedure    O
is    O
undertaken    O
,    O
a    O
patient    O
will    O
generally    O
have    O
had    O
other    O
blood    O
tests    O
to    O
find    O
diagnostic    O
clues    O
,    O
including    O
a    O
complete    O
blood    O
count    O
,    O
renal    O
function    O
and    O
electrolytes    O
,    O
liver    B-Assay100791527
enzyme    I-Assay100791527
,    O
thyroid    O
function    O
tests    O
,    O
vitamin    O
B12    O
and    O
folic    O
acid    O
levels    O
.    O

Liver    B-Assay100791527
function    I-Assay100791527
test    I-Assay100791527
may    O
be    O
elevated    O
,    O
particularly    O
involving    O
GGT    O
and    O
ALP    O
,    O
with    O
ultrasound    O
and    O
CT    O
scans    O
being    O
considered    O
medical    O
imaging    O
investigations    O
of    O
choice    O
.    O

Tests    O
such    O
as    O
bilirubin    O
and    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
may    O
reveal    O
if    O
there    O
is    O
inflammation    O
linked    O
to    O
the    O
biliary    O
tree    O
or    O
gallbladder    O
,    O
and    O
whether    O
this    O
is    O
associated    O
with    O
inflammation    O
of    O
the    O
liver    O
,    O
and    O
a    O
lipase    O
or    O
amylase    O
may    O
be    O
elvated    O
if    O
there    O
is    O
pancreatitis    O
.    O

Routine    O
complete    O
blood    O
count    O
(    O
CBC    O
)    O
,    O
basic    O
metabolic    O
profile    O
,    O
liver    B-Assay100791527
enzymes    I-Assay100791527
,    O
and    O
coagulation    O
should    O
be    O
performed    O
.    O

Elevation    O
of    O
liver    B-Assay100791527
enzyme    I-Assay100791527
activities    O
,    O
such    O
a    O
glutamate    O
dehydrogenase    O
(    O
GLDH    O
)    O
,    O
gamma    O
-    O
glutamyl    O
transferase    O
(    O
GGT    O
)    O
,    O
and    O
lactate    O
dehydrogenase    O
(    O
LDH    O
)    O
,    O
is    O
detected    O
in    O
subacute    O
or    O
chronic    O
fasciolosis    O
from    O
12    O
to    O
15    O
weeks    O
after    O
ingestion    O
of    O
metacercariae    O
.    O

Routine    O
blood    O
tests    O
show    O
features    O
of    O
acute    O
inflammation    O
(    O
raised    O
white    O
blood    O
cell    O
count    O
and    O
elevated    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
level    O
)    O
,    O
and    O
usually    O
abnormal    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
(    O
LFTs    O
)    O
.    O

Liver    B-Assay100791527
enzyme    I-Assay100791527
elevations    O
are    O
common    O
,    O
but    O
clinically    O
significant    O
liver    O
disease    O
is    O
not    O
.    O

Blood    O
tests    O
may    O
be    O
used    O
,    O
particularly    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
,    O
and    O
other    O
blood    O
tests    O
may    O
be    O
used    O
to    O
investigate    O
the    O
presence    O
of    O
the    O
Hepatitis    O
viruses    O
in    O
the    O
blood    O
,    O
and    O
ultrasound    O
used    O
.    O

AST    O
is    O
commonly    O
measured    O
clinically    O
as    O
a    O
part    O
of    O
diagnostic    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
,    O
to    O
determine    O
liver    O
health    O
.    O

Often    O
,    O
elevated    O
LFT    B-Assay100791527
results    O
as    O
well    O
as    O
serum    O
bile    O
acid    O
counts    O

The    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
(    O
LFTs    O
)    O
is    O
a    O
simple    O
blood    O
test    O
,    O
the    O
results    O
of    O
which    O
should    O
be    O
available    O
by    O
the    O
next    O
day    O
.    O

1,5-Anhydroglucitol    B-Assay100791527
,    O
also    O
known    O
as    O
1,5-AG    B-Assay100791527
,    O
is    O
a    O
naturally    O
occurring    O
monosaccharide    O
found    O
in    O
nearly    O
all    O
foods    O
.    O

The    O
RDW    B-Assay100791527
is    O
increased    O
with    O
the    O
red    O
blood    O
cell    O
histogram    O
shifted    O
to    O
the    O
left    O
.    O

TRH    O
is    O
used    O
clinically    O
by    O
intravenous    O
injection    O
(    O
brand    O
name    O
Relefact    O
TRH    O
)    O
to    O
test    O
the    O
response    O
of    O
the    O
anterior    O
pituitary    O
gland    O
;    O
this    O
procedure    O
is    O
known    O
as    O
a    O
TRH    B-Assay100791527
test    I-Assay100791527
.    O

|rowspan=2|    O
Random    B-Assay100791527
glucose    I-Assay100791527

|    O
Mean    B-Assay100791527
platelet    I-Assay100791527
volume    I-Assay100791527
(    O
MPV    O
)    O

The    O
test    O
involves    O
placing    O
a    O
faecal    O
sample    O
on    O
guaiac    B-Assay100791527
paper    O
(    O
containing    O
a    O
phenolic    O
compound    O
,    O
alpha    O
-    O
guaiaconic    O
acid    O
,    O
extracted    O
from    O
the    O
wood    O
resin    O
of    O
Guaiacum    O
trees    O
)    O
and    O
applying    O
hydrogen    O
peroxide    O
which    O
,    O
in    O
the    O
presence    O
of    O
blood    O
,    O
yields    O
a    O
blue    O
reaction    O
product    O
within    O
seconds    O
.    O

Stool    B-Assay100791527
guaiac    I-Assay100791527
test    I-Assay100791527
,    O
a    O
test    O
for    O
the    O
presence    O
for    O
occult    O
blood    O

In    O
fetal    O
electrocardiography    O
,    O
ST    O
waveform    O
analysis    O
(    O
sometimes    O
abbreviated    O
STAN    O
)    O
is    O
used    O
to    O
get    O
an    O
indication    O
of    O
increasing    O
levels    O
of    O
fetal    O
base    B-Assay100791527
deficit    I-Assay100791527
.    O

Viral    O
load    O
tests    O
can    O
also    O
be    O
used    O
to    O
diagnose    O
HIV    O
infection    O
,    O
especially    O
in    O
children    O
under    O
18    O
months    O
born    O
to    O
mothers    O
with    O
HIV    O
,    O
where    O
the    O
presence    O
of    O
maternal    O
antibodies    O
prevents    O
the    O
use    O
of    O
antibody    O
-    O
based    O
(    O
ELISA    O
)    O
diagnostic    B-Assay100791527
tests    I-Assay100791527
.    O

The    O
Abbott    O
ARCHITECT    B-Assay100791527
HIV    I-Assay100791527
Ag/Ab    I-Assay100791527
combo    I-Assay100791527
test    I-Assay100791527
,    O
a    O
fourth    O
-    O
generation    O
test    O
,    O
has    O
an    O
increased    O
sensitivity    O
for    O
detecting    O
infections    O
during    O
the    O
acute    O
phase    O
(    O
when    O
compared    O
to    O
1st    O
and    O
3rd    O
generation    O
tests    O
)    O
,    O
when    O
the    O
immune    O
system    O
is    O
still    O
developing    O
antibodies    O
and    O
the    O
virus    O
is    O
replicating    O
unchecked    O
,    O
and    O
in    O
one    O
study    O
,    O
was    O
able    O
to    O
detect    O
83%    O
of    O
such    O
infections    O
.    O

She    O
was    O
also    O
a    O
strong    O
proponent    O
of    O
a    O
policy    O
,    O
which    O
was    O
successfully    O
passed    O
in    O
1987    O
,    O
to    O
protect    O
municipal    O
employees    O
from    O
discrimination    O
or    O
harassment    O
on    O
the    O
basis    O
of    O
HIV    B-Assay100791527
status    I-Assay100791527
.    O

Checkpoint    B-Assay100791527
was    O
the    O
name    O
of    O
the    O
first    O
rapid    O
HIV    B-Assay100791527
test    I-Assay100791527
facility    O
in    O
the    O
Netherlands    O
.    O

HIV    B-Assay100791527
test    I-Assay100791527
and    O
CD4    O
count    O

In    O
that    O
position    O
he    O
supervised    O
the    O
Department    O
’s    O
media    O
and    O
public    O
education    O
campaigns    O
on    O
severals    O
topics    O
,    O
such    O
as    O
smoking    O
cessation    O
,    O
HIV    O
prevention    O
and    O
testing    B-Assay100791527
,    O
anti    O
-    O
obesity    O
,    O
Ebola    O
,    O
influenza    O
,    O
and    O
immunization    O
.    O

Vice    O
President    O
George    O
W.    O
Bush    O
spoke    O
at    O
the    O
conference    O
on    O
the    O
topic    O
of    O
confidentiality    O
of    O
HIV    B-Assay100791527
test    I-Assay100791527
,    O
for    O
which    O
the    O
government    O
was    O
developing    O
a    O
policy    O
.    O

He    O
tested    B-Assay100791527
negative    O
for    O
HIV    O
fourteen    O
months    O
after    O
three    O
initial    O
tests    O
returned    O
a    O
positive    O
result    O
.    O

The    O
more    O
specific    O
and    O
sensitive    O
RT-PCR    B-Assay100791527
test    I-Assay100791527
for    O
HIV    O
's    O
genome    O
does    O
not    O
appear    O
to    O
have    O
been    O
performed    O
.    O

The    O
AIDS    O
Research    O
Centre    O
in    O
Baghdad    O
,    O
where    O
most    O
cases    O
have    O
been    O
diagnosed    O
,    O
provides    O
free    O
treatment    O
,    O
and    O
testing    B-Assay100791527
is    O
mandatory    O
for    O
foreigners    O
entering    O
Iraq    O
.    O

In    O
Joy    O
Mining    O
Machinery    O
v    O
NUMSA    O
,    O
an    O
important    O
case    O
in    O
South    O
African    O
labour    O
law    O
,    O
the    O
court    O
held    O
that    O
the    O
following    O
considerations    O
should    O
be    O
taken    O
into    O
account    O
in    O
determining    O
whether    O
or    O
not    O
HIV    B-Assay100791527
testing    I-Assay100791527
by    O
employers    O
of    O
their    O
employees    O
is    O
justifiable    O
:    O

These    O
included    O
HIV    B-Assay100791527
testing    I-Assay100791527
,    O
safer    O
sex    O
counseling    O
,    O
treatment    O
of    O
sexually    O
transmitted    O
infections    O
and    O
provision    O
of    O
condoms    O
.    O

Whitman    O
-    O
Walker    O
adopted    O
oral    B-Assay100791527
testing    I-Assay100791527
for    I-Assay100791527
HIV    I-Assay100791527
in    O
1993    O
before    O
most    O
major    O
AIDS    O
clinics    O
in    O
the    O
U.S.    O
That    O
same    O
year    O
,    O
WWC    O
built    O
the    O
Elizabeth    O
Taylor    O
Medical    O
Center    O
,    O
named    O
in    O
honor    O
of    O
actress    O
and    O
AIDS    O
activist    O
Dame    O
Elizabeth    O
Taylor    O
.    O

Brandon    O
Vandenburg    O
,    O
Cory    O
Batey    O
,    O
Brandon    O
Banks    O
and    O
Jaborian    O
McKenzie    O
were    O
taken    O
into    O
custody    O
and    O
given    O
a    O
state    O
mandated    O
HIV    B-Assay100791527
test    I-Assay100791527
.    O

Expected    O
DLCO    O
is    O
also    O
affected    O
by    O
the    O
amount    O
of    O
hemoglobin    O
,    O
carboxyhemoglobin    B-Assay100791527
,    O
age    O
and    O
sex    O
.    O

Hemoglobin    O
bound    O
to    O
carbon    O
monoxide    O
is    O
known    O
as    O
carboxyhemoglobin    B-Assay100791527
.    O

A    O
heme    O
unit    O
of    O
human    O
carboxyhemoglobin    B-Assay100791527
,    O
showing    O
the    O
carbonyl    O
ligand    O
at    O
the    O
apical    O
position    O
,    O
"    O
trans    O
"    O
to    O
the    O
histidine    O
residue    O
..    O

Researchers    O
reported    O
in    O
the    O
International    O
Journal    O
of    O
Cardiology    O
,    O
"    O
Marijuana    O
use    O
by    O
older    O
people    O
,    O
particularly    O
those    O
with    O
some    O
degree    O
of    O
coronary    O
artery    O
or    O
cerebrovascular    O
disease    O
,    O
poses    O
greater    O
risks    O
due    O
to    O
the    O
resulting    O
increase    O
in    O
catecholamines    O
,    O
cardiac    O
workload    O
,    O
and    O
carboxyhemoglobin    B-Assay100791527
levels    O
,    O
and    O
concurrent    O
episodes    O
of    O
profound    O
postural    O
hypotension    O
.    O

Metal    O
carbonyls    O
are    O
toxic    O
by    O
skin    O
contact    O
,    O
inhalation    O
or    O
ingestion    O
,    O
in    O
part    O
because    O
of    O
their    O
ability    O
to    O
carbonylate    O
hemoglobin    O
to    O
give    O
carboxyhemoglobin    B-Assay100791527
,    O
which    O
prevents    O
the    O
binding    O
of    O
O2    O
.    O

Mixing    B-Assay100791527
studies    I-Assay100791527
are    O
tests    O
performed    O
on    O
blood    O
plasma    O
used    O
to    O
distinguish    O
factor    O
deficiencies    O
from    O
factor    O
inhibitors    O
,    O
such    O
as    O
lupus    O
anticoagulant    O
,    O
or    O
specific    O
factor    O
inhibitors    O
,    O
such    O
as    O
antibodies    O
directed    O
against    O
factor    O
VIII    O
.    O

Merthiolate-Iodine-Formaldehyde    B-Assay100791527
(MIF)    I-Assay100791527
is    O
a    O
solution    O
used    O
in    O
biomedical    O
laboratories    O
for    O
concentration    O
of    O
stool    O
samples    O
prior    O
to    O
microscopic    O
investigation    O
for    O
parasites    O
.    O

When    O
there    O
are    O
sufficient    O
grounds    O
to    O
suspect    O
G6PD    O
,    O
a    O
direct    O
test    O
for    O
G6PD    O
is    O
the    O
"    O
Beutler    B-Assay100791527
fluorescent    I-Assay100791527
spot    I-Assay100791527
test    I-Assay100791527
"    O
,    O
which    O
has    O
largely    O
replaced    O
an    O
older    O
test    O
(    O
the    O
Motulsky    O
dye    O
-    O
decolouration    O
test    O
)    O
.    O

Fasting    B-Assay100791527
blood    I-Assay100791527
sugar    I-Assay100791527

The    O
two    O
principle    O
tests    O
used    O
to    O
determine    O
insulin    O
resistance    O
are    O
the    O
fasting    B-Assay100791527
plasma    I-Assay100791527
glucose    I-Assay100791527
test    O
(    O
FPG    O
)    O
and    O
the    O
oral    O
glucose    O
tolerance    O
test    O
(    O
GTT    O
)    O
.    O

Fasting    B-Assay100791527
glucose    I-Assay100791527
:    O
0.198(0.075    O
)    O
,    O
0.22(0.059    O
)    O
,    O
0.10(0.05    O
)    O
,    O
0.17(0.061    O
)    O

He    O
is    O
also    O
credited    O
with    O
discovering    O
Cabot    B-Assay100791527
rings    I-Assay100791527
,    O
and    O
for    O
describing    O
,    O
along    O
with    O
his    O
colleague    O
,    O
Locke    O
,    O
the    O
eponymous    O
Cabot    O
-    O
Locke    O
murmur    O
,    O
a    O
diastolic    O
murmur    O
occasionally    O
heard    O
in    O
severe    O
anemia    O
,    O
unrelated    O
to    O
heart    O
valve    O
abnormalities    O
.    O

Widal    B-Assay100791527
test    I-Assay100791527

The    O
Sudan    B-Assay100791527
dye    I-Assay100791527
are    O
a    O
group    O
of    O
azo    O
compounds    O
which    O
have    O
been    O
used    O
to    O
color    O
hydrocarbon    O
solvents    O
,    O
oils    O
,    O
fats    O
,    O
waxes    O
,    O
shoes    O
,    O
and    O
floor    O
polishes    O
.    O

The    O
tissue    O
parts    O
that    O
specifically    O
stain    O
by    O
this    O
dye    O
become    O
blue    O
to    O
bluish    O
-    O
green    O
after    O
staining    O
and    O
are    O
called    O
"    O
Alcianophilic    O
"    O
(    O
akin    O
to    O
"    O
eosinophilic    O
"    O
or    O
"    O
sudanophilic    B-Assay100791527
"    O
)    O
.    O

Morten    O
Ansgar    O
Kveim    O
(    O
27    O
December    O
189    O
–    O
24    O
March    O
1966    O
)    O
was    O
a    O
Norwegian    O
pathologist    O
most    O
remembered    O
for    O
describing    O
the    O
Kveim    B-Assay100791527
test    I-Assay100791527
.    O

---    O
osmotic    B-Assay100791527
fragility    I-Assay100791527

Red    O
blood    O
cells    O
have    O
been    O
assayed    O
in    O
terms    O
of    O
deformability    O
,    O
osmotic    B-Assay100791527
fragility    I-Assay100791527
,    O
hemolysis    O
,    O
ATP    O
level    O
,    O
and    O
hemoglobin    O
content    O
.    O

Induration    O
of    O
5    O
mm    O
or    O
more    O
with    O
erythema    O
(    O
redness    O
)    O
,    O
or    O
10    O
mm    O
without    O
,    O
48    O
hours    O
post    O
injection    O
are    O
positive    O
Fernandez    B-Assay100791527
reaction    I-Assay100791527
.    O

Josef    O
Arneth    O
(    O
13    O
October    O
1873    O
in    O
Burgkunstadt    O
–    O
1955    O
)    O
was    O
a    O
German    O
physician    O
and    O
haematologist    O
known    O
for    O
naming    O
the    O
Arneth    B-Assay100791527
count    I-Assay100791527
.    O

Reference    B-Assay100791527
ranges    I-Assay100791527
for    I-Assay100791527
blood    I-Assay100791527
tests    I-Assay100791527
,    O
showing    O
acid    O
phosphatase    O
in    O
red    O
at    O
left    O
.    O

Reference    B-Assay100791527
ranges    I-Assay100791527
for    I-Assay100791527
blood    I-Assay100791527
tests    I-Assay100791527

Reference    B-Assay100791527
ranges    I-Assay100791527
for    I-Assay100791527
blood    I-Assay100791527
tests    I-Assay100791527
,    O
showing    O
adrenocorticotropic    O
hormone    O
(    O
green    O
at    O
left    O
)    O
among    O
the    O
hormones    O
with    O
smallest    O
concentration    O
in    O
the    O
blood    O
.    O

Reference    B-Assay100791527
ranges    I-Assay100791527
for    I-Assay100791527
blood    I-Assay100791527
tests    I-Assay100791527
,    O
showing    O
C    O
-    O
reactive    O
protein    O
in    O
brown    O
-    O
yellow    O
in    O
center    O
.    O

Reference    B-Assay100791527
ranges    I-Assay100791527
for    I-Assay100791527
blood    I-Assay100791527
tests    I-Assay100791527
of    O
white    O
blood    O
cells    O
,    O
comparing    O
monocyte    O
amount    O
(    O
shown    O
in    O
green    O
)    O
with    O
other    O
cells    O
.    O

Propafenone    O
is    O
metabolized    O
primarily    O
in    O
the    O
liver    O
.    O
Because    O
of    O
its    O
short    O
half    O
-    O
life    O
,    O
it    O
requires    O
dosing    O
two    O
or    O
three    O
times    O
daily    O
to    O
maintain    O
steady    O
blood    B-Assay100791527
levels    I-Assay100791527
.    O

The    O
normal    O
white    O
cell    O
count    O
is    B-Assay100791527
usually    I-Assay100791527
between    O
4    O
×    O
109/L    O
and    O
11    O
×    O
109/L.    O
In    O
the    O
US    O
this    O
is    O
usually    O
expressed    O
as    O
4,000    O
to    O
11,000    O
white    O
blood    O
cells    O
per    O
microliter    O
of    O
blood    O
.    O

Reference    B-Assay100791527
ranges    I-Assay100791527
for    I-Assay100791527
blood    I-Assay100791527
tests    I-Assay100791527
specify    O
the    O
typical    O
counts    O
in    O
healthy    O
people    O
.    O

However    O
,    O
different    O
assays    O
and    O
methods    O
for    O
measuring    O
prolactin    O
are    O
employed    O
by    O
different    O
laboratories    O
and    O
as    O
such    O
the    O
serum    B-Assay100791527
reference    I-Assay100791527
range    I-Assay100791527
for    O
prolactin    O
is    O
often    O
determined    O
by    O
the    O
laboratory    O
performing    O
the    O
measurement    O
.    O

Reference    B-Assay100791527
ranges    I-Assay100791527
for    I-Assay100791527
common    I-Assay100791527
blood    I-Assay100791527
tests    I-Assay100791527

His    O
very    O
public    O
revelation    O
and    O
reporting    O
of    O
his    O
condition    O
was    O
(    O
according    O
to    O
Jarvis    O
)    O
partially    O
motivated    O
by    O
,    O
in    O
his    O
words    O
,    O
the    O
hope    O
"    O
to    O
be    O
one    O
more    O
guy    O
to    O
convince    O
you    O
men    O
to    O
get    O
your    O
PSA    B-Assay100791527
checked    O
:    O
a    O
small    O
mitzvah    O
in    O
return    O
for    O
my    O
luck    O
.    O
"    O

It    O
showed    O
signs    O
of    O
efficacy    O
in    O
the    O
form    O
of    O
prostatic    B-Assay100791527
specific    I-Assay100791527
antigen    I-Assay100791527
(    O
PSA    O
)    O
decreases    O
(    O
4–29%    O
)    O
predominantly    O
at    O
higher    O
doses    O
(    O
≥1,280    O
mg    O
)    O
in    O
some    O
patients    O
but    O
also    O
caused    O
side    O
effects    O
and    O
was    O
discontinued    O
by    O
its    O
developer    O
in    O
favor    O
of    O
next    O
-    O
generation    O
AR    O
NTD    O
inhibitors    O
with    O
improved    O
potency    O
and    O
tolerability    O
.    O

This    O
in    O
turn    O
results    O
in    O
a    O
reduction    O
in    O
prostate-specific    B-Assay100791527
antigen    I-Assay100791527
(    O
PSA    O
)    O
levels    O
in    O
the    O
patient    O
's    O
blood    O
.    O

Secondly    O
,    O
they    O
strongly    O
encourage    O
the    O
exclusion    O
of    O
confusable    O
diseases    O
through    O
an    O
extensive    O
and    O
expensive    O
series    O
of    O
tests    O
including    O
(    O
A    O
)    O
a    O
medical    O
history    O
and    O
physical    O
exam    O
,    O
(    O
B    O
)    O
a    O
dipstick    O
urinalysis    O
,    O
various    O
urine    O
cultures    O
,    O
and    O
a    O
serum    O
PSA    B-Assay100791527
in    O
men    O
over    O
40    O
,    O
(    O
C    O
)    O
flowmetry    O
and    O
post    O
-    O
void    O
residual    O
urine    O
volume    O
by    O
ultrasound    O
scanning    O
and    O
(    O
D    O
)    O
cystoscopy    O
.    O

|    O
Prostate    B-Assay100791527
specific    I-Assay100791527
antigen    I-Assay100791527
(    O
PSA    O
)    O

KLK3    B-Assay100791527
:    O
The    O
Prostate    O
-    O
specific    O
antigen    O
(    O
PSA    O
)    O

PROSTVAC    O
is    O
a    O
vaccine    O
designed    O
to    O
enable    O
the    O
immune    O
system    O
to    O
recognize    O
and    O
attack    O
prostate    O
cancer    O
cells    O
by    O
triggering    O
a    O
specific    O
and    O
targeted    O
T    O
cell    O
immune    O
response    O
to    O
cancer    O
cells    O
that    O
express    O
the    O
tumor    O
-    O
associated    O
antigen    O
prostate-specific    B-Assay100791527
antigen    I-Assay100791527
(    O
PSA    O
)    O
.    O

LNCaP    O
cells    O
also    O
express    O
Prostate    B-Assay100791527
Specific    I-Assay100791527
Antigen    I-Assay100791527
(    O
PSA    O
)    O
.    O
"    O
In    O
vivo    O
"    O
,    O
Male    O
mice    O
develop    O
tumors    O
earlier    O
and    O
at    O
a    O
greater    O
frequency    O
than    O
do    O
females    O
and    O
hormonal    O
manipulations    O
show    O
that    O
the    O
frequency    O
of    O
tumor    O
development    O
correlates    O
with    O
serum    O
androgen    O
levels    O
.    O

Parental    O
LNCaP    O
,    O
M    O
,    O
C4    O
,    O
and    O
C5    O
subline    O
have    O
similar    O
baseline    O
gene    O
expression    O
levels    O
of    O
ornithine    O
decarboxylase    O
(    O
ODC    O
)    O
and    O
Prostate    B-Assay100791527
Specific    I-Assay100791527
Antigen    I-Assay100791527
(    O
PSA    O
)    O
however    O
,    O
M    O
,    O
C4    O
,    O
and    O
C5    O
sublines    O
express    O
5    O
-    O
10X    O
more    O
PSA    O
mRNA    O
.    O

During    O
the    O
festival    O
,    O
Paulie    O
is    O
tested    O
for    O
prostate    O
cancer    O
because    O
of    O
an    O
elevated    O
PSA    B-Assay100791527
.    O

Other    O
clinical    O
immunoassays    O
include    O
tests    O
that    O
measure    O
levels    O
of    O
CK    O
-    O
MB    O
to    O
assess    O
heart    O
disease    O
,    O
insulin    O
to    O
assess    O
hypoglycemia    O
,    O
prostate-specific    B-Assay100791527
antigen    I-Assay100791527
to    O
detect    O
prostate    O
cancer    O
,    O
and    O
some    O
are    O
also    O
used    O
for    O
the    O
detection    O
and/or    O
quantitative    O
measurement    O
of    O
some    O
pharmaceutical    O
compounds    O
(    O
see    O
Enzyme    B-Assay100791527
multiplied    I-Assay100791527
immunoassay    I-Assay100791527
technique    I-Assay100791527
for    O
more    O
details    O
)    O
.    O

In    O
the    O
early    O
1980s    O
,    O
Morris    O
was    O
the    O
first    O
to    O
clone    O
the    O
gene    O
for    O
human    O
renin    O
,    O
as    O
well    O
as    O
the    O
first    O
human    O
kallikrein    O
gene    O
(    O
showing    O
that    O
it    O
was    O
prostate    O
-    O
specific    O
,    O
relevant    O
to    O
prostate    O
cancer    O
screening    O
,    O
just    O
as    O
its    O
closest    O
relative    O
PSA    B-Assay100791527
)    O
.    O

He    O
discovered    O
that    O
he    O
had    O
the    O
cancer    O
following    O
his    O
participation    O
in    O
a    O
charity    O
event    O
in    O
aid    O
of    O
a    O
prostate    O
cancer    O
charity    O
,    O
where    O
a    O
representative    O
of    O
the    O
charity    O
asked    O
whether    O
,    O
as    O
a    O
man    O
over    O
50    O
,    O
he    O
had    O
had    O
a    O
PSA    B-Assay100791527
test    I-Assay100791527
.    O

Examples    O
of    O
tumoral    O
markers    O
used    O
to    O
follow    O
up    O
cancer    O
treatment    O
are    O
the    O
Carcinoembryonic    O
Antigen    O
(    O
CEA    O
)    O
for    O
colorectal    O
cancer    O
and    O
the    O
Prostate    B-Assay100791527
Specific    I-Assay100791527
Antigen    I-Assay100791527
(    O
PSA    O
)    O
for    O
prostate    O
cancer    O
.    O

The    O
lepromin    B-Assay100791527
skin    I-Assay100791527
test    I-Assay100791527
is    O
used    O
to    O
determine    O
what    O
type    O
of    O
leprosy    O
a    O
person    O
has    O
.    O

In    O
1914    O
,    O
together    O
with    O
R.    O
Klinger    O
,    O
Hirszfeld    O
developed    O
a    O
serodiagnostic    O
reaction    O
test    O
for    O
syphilis    O
,    O
which    O
did    O
not    O
,    O
however    O
,    O
replace    O
the    O
Wasserman    B-Assay100791527
test    I-Assay100791527
introduced    O
in    O
1906    O
.    O

One    O
year    O
later    O
,    O
the    O
first    O
effective    O
test    O
for    O
syphilis    O
,    O
the    O
Wassermann    B-Assay100791527
test    I-Assay100791527
,    O
was    O
developed    O
.    O

He    O
was    O
the    O
first    O
to    O
describe    O
his    O
triad    O
of    O
medical    O
signs    O
for    O
congenital    O
syphilis    O
:    O
notched    O
incisor    O
teeth    O
,    O
labyrinthine    O
deafness    O
and    O
interstitial    O
keratitis    O
,    O
which    O
was    O
very    O
useful    O
for    O
providing    O
a    O
firm    O
diagnosis    O
long    O
before    O
the    O
"    O
Treponema    O
pallidum    O
"    O
or    O
the    O
Wassermann    B-Assay100791527
test    I-Assay100791527
were    O
discovered    O
.    O

|    O
Antistreptolysin    B-Assay100791527
O    I-Assay100791527
titre    I-Assay100791527
(    O
ASOT    O
)    O
in    O
preschoolers    O

Diagnosis    O
may    O
be    O
made    O
on    O
clinical    O
findings    O
or    O
through    O
antistreptolysin    B-Assay100791527
O    I-Assay100791527
antibodies    O
found    O
in    O
the    O
blood    O
.    O

Blood    O
tests    O
investigating    O
the    O
cause    O
,    O
including    O
FBC    O
,    O
inflammatory    O
markers    O
and    O
special    O
tests    O
including    O
(    O
ASLO    B-Assay100791527
,    O
ANCA    B-Assay100791527
,    O
Anti    O
-    O
GBM    O
,    O
Complement    O
levels    O
,    O
Antinuclear    O
antibodies    O

|    O
Transferrin    B-Assay100791527
saturation    I-Assay100791527

High    O
transferrin    B-Assay100791527
saturation    I-Assay100791527

The    O
Kato-Katz    B-Assay100791527
method    I-Assay100791527
and    O
molecular    O
techniques    O
such    O
as    O
polymerase    O
chain    O
reaction    O
(    O
PCR    O
)    O
can    O
be    O
used    O
to    O
distinguish    O
hookworm    O
species    O
,    O
but    O
are    O
not    O
always    O
effective    O
at    O
doing    O
so    O
.    O
Sequencing    O
of    O
ribosomal    O
RNA    O
gene    O
is    O
often    O
reliable    O
but    O
time    O
consuming    O
.    O

Kato    B-Assay100791527
technique    I-Assay100791527

specific    O
factor    O
assays    O
,    O
like    O
fibrin    O
degradation    O
products    O
,    O
D-dimer    B-Assay100791527
,    O
thrombin    B-Assay100791527
time    I-Assay100791527
,    O
platelet    O
aggregation    O
,    O
or    O

Thus    O
,    O
the    O
reptilase    O
time    O
is    O
not    O
prolonged    O
in    O
blood    O
samples    O
containing    O
heparin    O
,    O
hirudin    O
,    O
or    O
direct    O
thrombin    O
inhibitors    O
,    O
whereas    O
the    O
thrombin    B-Assay100791527
time    I-Assay100791527
will    O
be    O
prolonged    O
in    O
these    O
samples    O
.    O

|    O
Thrombin    B-Assay100791527
clotting    I-Assay100791527
time    I-Assay100791527
(    O
TCT    O
)    O

Steatorrhea    O
can    O
be    O
diagnosed    O
using    O
a    O
Fecal    B-Assay100791527
fat    I-Assay100791527
test    O
that    O
checks    O
for    O
the    O
malabsorption    O
of    O
fat    O
.    O

In    O
1943    O
he    O
worked    O
as    O
a    O
medical    O
officer    O
in    O
the    O
U.S.    B-Assay100791527
Public    I-Assay100791527
Health    I-Assay100791527
Venereal    I-Assay100791527
Disease    I-Assay100791527
Research    I-Assay100791527
Laboratory    I-Assay100791527
on    O
Staten    O
Island    O
.    O

syphilis    O
ACA    O
are    O
beta-2    O
glycoprotein    O
independent    O
and    O
can    O
be    O
assayed    O
using    O
the    O
Venereal    B-Assay100791527
Disease    I-Assay100791527
Research    I-Assay100791527
Laboratory    I-Assay100791527
test    I-Assay100791527

Magnetic    B-Assay100791527
immunoassay    I-Assay100791527

Magnetic    B-Assay100791527
immunoassay    I-Assay100791527

Sepsis    O
from    O
prostatitis    O
is    O
very    O
rare    O
,    O
but    O
may    O
occur    O
in    O
immunocompromised    O
patients    O
;    O
high    O
fever    O
and    O
malaise    O
generally    O
prompt    O
blood    B-Assay100791527
culture    I-Assay100791527
,    O
which    O
are    O
often    O
positive    O
in    O
sepsis    O
.    O

Skin    O
aspiration    O
of    O
nonpurulent    O
cellulitis    O
,    O
usually    O
caused    O
by    O
streptococcal    O
organisms    O
,    O
is    O
rarely    O
helpful    O
for    O
diagnosis    O
,    O
and    O
blood    B-Assay100791527
culture    I-Assay100791527
are    O
positive    O
in    O
fewer    O
than    O
5%    O
of    O
all    O
cases    O
.    O

In    O
the    O
1930s    O
microbiology    O
was    O
a    O
focus    O
,    O
with    O
many    O
of    O
those    O
projects    O
reliant    O
upon    O
blood    B-Assay100791527
cultures    I-Assay100791527
and    O
the    O
techniques    O
developed    O
were    O
published    O
in    O
a    O
monograph    O
–    O
"    O

Common    O
tests    O
include    O
Gram    O
staining    O
,    O
blood    B-Assay100791527
cultures    I-Assay100791527
,    O
serological    O
tests    O
,    O
genotyping    O
,    O
and    O
polymerase    O
chain    O
reaction    O
(    O
PCR    O
)    O
.    O

Blood    B-Assay100791527
culture    I-Assay100791527
are    O
often    O
performed    O
in    O
people    O
with    O
fever    O
and    O
evidence    O
of    O
acute    O
infection    O
.    O

The    O
diagnosis    O
is    O
made    O
with    O
serologic    O
methods    O
,    O
either    O
the    O
classic    O
Weil-Felix    B-Assay100791527
test    I-Assay100791527

Winifred    O
Mayer    O
Ashby    O
(    O
October    O
13    O
,    O
1879    O
-    O
July    O
19    O
,    O
1975    O
)    O
was    O
a    O
British    O
-    O
born    O
American    O
pathologist    O
known    O
for    O
developing    O
the    O
Ashby    B-Assay100791527
technique    I-Assay100791527
for    O
determining    O
red    O
blood    O
cell    O
survival    O
.    O

Agglutination    O
of    O
red    O
blood    O
cells    O
is    O
used    O
in    O
the    O
Coombs    B-Assay100791527
test    I-Assay100791527
.    O

To    O
bind    O
antibodies    O
to    O
cells    O
such    O
as    O
erythrocytes    O
in    O
advance    O
of    O
performing    O
an    O
immunological    O
test    O
such    O
as    O
a    O
complement    O
-    O
fixation    O
test    O
or    O
a    O
Coombs    B-Assay100791527
test    I-Assay100791527
.    O

Coombs    B-Assay100791527
test    I-Assay100791527
,    O
an    O
aid    O
to    O
medical    O
diagnosis    O
.    O

Antibodies    O
directed    O
against    O
red    O
blood    O
cell    O
surface    O
antigens    O
in    O
immune    O
mediated    O
hemolytic    O
anemia    O
are    O
detected    O
with    O
the    O
Coombs    B-Assay100791527
test    I-Assay100791527
.    O

Signs    O
of    O
hemolytic    O
disease    O
of    O
the    O
newborn    O
include    O
a    O
positive    O
direct    B-Assay100791527
Coombs    I-Assay100791527
test    I-Assay100791527
(    O
also    O
called    O
direct    O
agglutination    O
test    O
)    O
,    O
elevated    O
cord    O
bilirubin    O
,    O
and    O
hemolytic    O
anemia    O
.    O

Much    O
of    O
the    O
early    O
work    O
of    O
the    O
unit    O
was    O
concerned    O
with    O
identifying    O
genetic    O
variants    O
of    O
this    O
system    O
which    O
became    O
possible    O
after    O
the    O
initial    O
discovery    O
by    O
Karl    O
Landsteiner    O
and    O
the    O
development    O
of    O
the    O
Coombs    B-Assay100791527
test    I-Assay100791527
.    O

|rowspan=2|    O
Mean    B-Assay100791527
corpuscular    I-Assay100791527
hemoglobin    I-Assay100791527
concentration    I-Assay100791527
(    O
MCHC    O
)    O

Since    O
then    O
the    O
team    O
has    O
held    O
the    O
longest    O
tenure    O
in    O
its    O
current    O
league    O
the    O
Metropolitan    O
Collegiate    O
Hockey    O
Conference    O
(    O
MCHC    B-Assay100791527
)    O
after    O
the    O
MIHL    O
changed    O
its    O
name    O
during    O
the    O
1974–75    O
season    O
.    O

Diagnostic    O
markers    O
include    O
eosinophil    O
granulocytes    O
and    O
granulomas    O
in    O
affected    O
tissue    O
,    O
and    O
antineutrophil    B-Assay100791527
cytoplasmic    I-Assay100791527
antibodies    I-Assay100791527
(    O
ANCA    O
)    O
against    O
neutrophil    O
granulocytes    O
.    O

|    O
Cytoplasmic    O
/    O
classical    O
anti-neutrophil    B-Assay100791527
cytoplasmic    I-Assay100791527
antibodies    I-Assay100791527
(    O
c    O
-    O
ANCA    O
)    O

No    O
immune    O
deposits    O
can    O
be    O
seen    O
on    O
staining    O
,    O
however    O
blood    O
tests    O
may    O
be    O
positive    O
for    O
the    O
ANCA    B-Assay100791527
antibody    O
.    O

Blood    O
tests    O
investigating    O
the    O
cause    O
,    O
including    O
FBC    O
,    O
inflammatory    O
markers    O
and    O
special    O
tests    O
including    O
(    O
ASLO    B-Assay100791527
,    O
ANCA    B-Assay100791527
,    O
Anti    O
-    O
GBM    O
,    O
Complement    O
levels    O
,    O
Antinuclear    O
antibodies    O

:*    O
ANCA-associated    B-Assay100791527
vasculitis    I-Assay100791527

Rapid    B-Assay100791527
plasma    I-Assay100791527
reagin    I-Assay100791527

Marcus    O
returned    O
to    O
work    O
on    O
July    O
24    O
,    O
and    O
due    O
to    O
his    O
history    O
and    O
reputation    O
in    O
the    O
industry    O
he    O
was    O
not    O
asked    O
for    O
the    O
full    O
test    O
and    O
just    O
showed    O
the    O
producer    O
a    O
copy    O
on    O
his    O
cellphone    O
,    O
enabling    O
him    O
to    O
hide    O
the    O
rapid    B-Assay100791527
plasma    I-Assay100791527
reagin    I-Assay100791527
(    O
RPR    O
)    O
section    O
relevant    O
to    O
syphilis    O
.    O

Laboratory    O
tests    O
include    O
blood    O
tests    O
for    O
vitamin    O
B-12    O
levels    O
,    O
a    O
complete    O
blood    O
count    O
,    O
measurement    O
of    O
thyroid    O
stimulating    O
hormone    O
levels    O
,    O
a    O
comprehensive    B-Assay100791527
metabolic    I-Assay100791527
panel    I-Assay100791527
screening    O
for    O
diabetes    O
and    O
pre    O
-    O
diabetes    O
,    O
and    O
a    O
serum    O
immunofixation    O
test    O
,    O
which    O
tests    O
for    O
antibodies    O
in    O
the    O
blood    O
.    O

Comprehensive    B-Assay100791527
metabolic    I-Assay100791527
panel    I-Assay100791527

The    O
basic    O
metabolic    O
panel    O
is    O
a    O
simpler    O
version    O
of    O
the    O
comprehensive    B-Assay100791527
metabolic    I-Assay100791527
panel    I-Assay100791527
(    O
CMP    O
)    O
,    O
which    O
includes    O
tests    O
for    O
liver    O
function    O
.    O

It    O
is    O
common    O
to    O
perform    O
thyroid    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
,    O
assess    O
B12    O
,    O
rule    O
out    O
syphilis    O
,    O
rule    O
out    O
metabolic    O
problems    O
(    O
including    O
tests    O
for    O
kidney    O
function    O
,    O
electrolyte    O
levels    O
and    O
for    O
diabetes    O
)    O
,    O
assess    O
levels    O
of    O
heavy    O
metals    O
(    O
e.g.    O
lead    O
,    O
mercury    O
)    O
and    O
anaemia    O
.    O

Therapy    O
for    O
hyperthyroidism    O
generally    O
starts    O
at    O
a    O
high    O
daily    O
dose    O
of    O
continued    O
until    O
the    O
patient    O
has    O
normal    O
thyroid    B-Assay100791527
function    I-Assay100791527
,    O
and    O
then    O
reduced    O
to    O
a    O
maintenance    O
dose    O
of    O
.    O

TPP    O
is    O
distinguished    O
from    O
other    O
forms    O
of    O
periodic    O
paralysis    O
(    O
especially    O
hypokalemic    O
periodic    O
paralysis    O
)    O
with    O
thyroid    B-Assay100791527
function    I-Assay100791527
test    I-Assay100791527
on    O
the    O
blood    O
.    O

Thyroid    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
,    O
a    O
collective    O
term    O
for    O
blood    O
tests    O
used    O
to    O
check    O
the    O
function    O
of    O
the    O
thyroid    O

The    O
complete    O
blood    O
cell    O
count    O
is    O
a    O
blood    O
panel    O
that    O
includes    O
the    O
overall    O
WBC    O
count    O
and    O
various    O
subsets    O
such    O
as    O
the    O
absolute    B-Assay100791527
neutrophil    I-Assay100791527
count    I-Assay100791527
.    O

Reptilase    B-Assay100791527
time    I-Assay100791527
(    O
RT    O
)    O
is    O
a    O
blood    O
test    O
used    O
to    O
detect    O
deficiency    O
or    O
abnormalities    O
in    O
fibrinogen    O
,    O
especially    O
in    O
cases    O
of    O
heparin    O
contamination    O
.    O

Helper/suppressor    B-Assay100791527
ratio    I-Assay100791527

The    O
Mentzer    B-Assay100791527
index    I-Assay100791527
(    O
mean    O
cell    O
volume    O
divided    O
by    O
the    O
RBC    O
count    O
)    O
predicts    O
whether    O
microcytic    O
anemia    O
may    O
be    O
due    O
to    O
iron    O
deficiency    O
or    O
thallasemia    O
,    O
although    O
it    O
requires    O
confirmation    O
.    O

content    B-Assay100791527
(    O
also    O
known    O
as    O
"    O
Total    O
")    O
is    O
a    O
blood    O
test    O
that    O
usually    O
appears    O
on    O
a    O
"    O
Chem    O
19    O
"    O
or    O
an    O
electrolyte    O
panel    O
.    O

MELISA    B-Assay100791527

specific    O
factor    O
assays    O
,    O
like    O
fibrin    O
degradation    O
products    O
,    O
D-dimer    B-Assay100791527
,    O
thrombin    B-Assay100791527
time    I-Assay100791527
,    O
platelet    O
aggregation    O
,    O
or    O

A    O
2004    O
study    O
suggested    O
that    O
the    O
D-dimer    B-Assay100791527
blood    O
test    O
,    O
already    O
in    O
use    O
for    O
the    O
diagnosis    O
of    O
other    O
forms    O
of    O
thrombosis    O
,    O
was    O
abnormal    O
(    O
above    O
500    O

The    O
most    O
notable    O
subtype    O
of    O
fibrin    O
degradation    O
products    O
is    O
D-dimer    B-Assay100791527
.    O

Principles    O
of    O
D-dimer    B-Assay100791527
testing    O
.    O

It    O
is    O
a    O
phenylalanine    O
antagonist    O
used    O
in    O
the    O
Guthrie    B-Assay100791527
test    I-Assay100791527
.    O

One    O
method    O
is    O
a    O
post    O
-    O
parturition    O
screening    O
test    O
known    O
as    O
the    O
Guthrie    B-Assay100791527
Test    I-Assay100791527
.    O

Therefore    O
,    O
PAH    B-Assay100791527
clearance    I-Assay100791527
can    O
be    O
used    O
to    O
estimate    O
RPF    O
.    O

Volume    B-Assay100791527
status    I-Assay100791527

#    O
#    O
Cytometry    B-Assay100791527
:    O
When    O
the    O
size    O
statistics    O
of    O
cells    O
is    O
assessed    O
by    O
an    O
image    O
processor    O
.    O

Cytometry    O
Part    O
A    O
is    O
a    O
peer    O
-    O
reviewed    O
scientific    O
journal    O
covering    O
all    O
aspects    O
of    O
the    O
study    O
of    O
cytometry    B-Assay100791527
that    O
was    O
established    O
in    O
1980    O
.    O

Cytometry    B-Assay100791527

Protein    B-Assay100791527
electrophoresis    I-Assay100791527
,    O
method    O
of    O
analysing    O
a    O
mixture    O
of    O
proteins    O
by    O
means    O
of    O
gel    O
electrophoresis    O

Schematic    O
representation    O
of    O
a    O
protein    B-Assay100791527
electrophoresis    I-Assay100791527
gel    O
.    O

Protein    B-Assay100791527
electrophoresis    I-Assay100791527

Protein    B-Assay100791527
electrophoresis    I-Assay100791527
,    O
a    O
specific    O
type    O
of    O
gel    O
electrophoresis    O
used    O
to    O
analyse    O
proteins    O

Schematic    O
representation    O
of    O
a    O
protein    B-Assay100791527
electrophoresis    I-Assay100791527
gel    O
.    O

FibroTest    B-Assay100791527
,    O
known    O
as    O
FibroSure    O
in    O
the    O
US    O
,    O
is    O
a    O
biomarker    O
test    O
that    O
uses    O
the    O
results    O
of    O
six    O
blood    O
serum    O
tests    O
to    O
generate    O
a    O
score    O
that    O
is    O
correlated    O
with    O
the    O
degree    O
of    O
liver    O
damage    O
in    O
people    O
with    O
a    O
variety    O
of    O
liver    O
diseases    O
.    O

Basopenia    B-Assay100791527
(    O
or    O
basocytopenia    B-Assay100791527
)    O
is    O
a    O
form    O
of    O
agranulocytosis    O
associated    O
with    O
a    O
deficiency    O
of    O
basophils    O
.    O

Blood    B-Assay100791527
Urea    I-Assay100791527
Nitrogen    I-Assay100791527

While    O
in    O
the    O
blood    O
,    O
bicarbonate    O
ion    O
serves    O
to    O
neutralize    O
acid    O
introduced    O
to    O
the    O
blood    O
through    O
other    O
metabolic    O
processes    O
(    O
e.g.    O
lactic    O
acid    O
,    O
ketone    O
bodies    O
)    O
;    O
likewise    O
,    O
any    O
bases    O
(    O
e.g.    O
urea    B-Assay100791527
from    I-Assay100791527
the    I-Assay100791527
catabolism    I-Assay100791527
of    I-Assay100791527
proteins    I-Assay100791527
)    O
are    O
neutralized    O
by    O
carbonic    O
acid    O
.    O

A    O
simple    O
means    O
of    O
estimating    O
renal    O
function    O
is    O
to    O
measure    O
pH    O
,    O
blood    B-Assay100791527
urea    I-Assay100791527
nitrogen    I-Assay100791527
,    O
creatinine    O
,    O
and    O
basic    O
electrolytes    O
(    O
including    O
sodium    O
,    O
potassium    O
,    O
chloride    O
,    O
and    O
bicarbonate    O
)    O
.    O

Other    O
changes    O
in    O
blood    O
chemistry    O
such    O
as    O
hypomagnesemia    O
,    O
hypocalcemia    O
,    O
hyperkalemia    O
,    O
and    O
an    O
increase    O
in    O
blood    B-Assay100791527
urea    I-Assay100791527
nitrogen    I-Assay100791527
(    O
BUN    O
)    O
can    O
occur    O
.    O

Elevation    O
in    O
BUN    B-Assay100791527
(    O
1.2%    O
)    O

blood    B-Assay100791527
urea    I-Assay100791527
nitrogen    I-Assay100791527
(    O
BUN    O
)    O

A    O
blood    O
test    O
may    O
reveal    O
increases    O
in    O
blood    B-Assay100791527
urea    I-Assay100791527
nitrogen    I-Assay100791527
(    O
BUN    O
)    O
,    O
creatinine    O
,    O
phosphorus    O
,    O
and    O
calcium    O
.    O

From    O
in    O
-    O
person    O
interviews    O
and    O
physical    O
health    O
exams    O
after    O
about    O
two    O
years    O
of    O
coverage    O
,    O
researchers    O
examined    O
patient    O
health    O
issues    O
including    O
depression    O
,    O
high    O
blood    O
pressure    O
,    O
elevated    O
cholesterol    O
,    O
high    O
glycated    B-Assay100791527
hemoglobin    I-Assay100791527
levels    O
,    O
and    O
long    O
-    O
term    O
cardiovascular    O
risks    O
(    O
the    O
latter    O
using    O
the    O
Framingham    O
risk    O
score    O
)    O
.    O

The    O
HbA1c    B-Assay100791527
was    O
examined    O
after    O
SGLT-2    O
inhibitors    O
were    O
given    O
alone    O
(    O
as    O
monotherapy    O
)    O
or    O
as    O
an    O
add    O
-    O
on    O
therapy    O
to    O
the    O
other    O
diabetes    O
medicines    O
.    O

The    O
HbA1c    B-Assay100791527
was    O
examined    O
after    O
SGLT-2    O
inhibitors    O
were    O
given    O
alone    O
(    O
as    O
monotherapy    O
)    O
or    O
as    O
an    O
add    O
-    O
on    O
therapy    O
to    O
the    O
other    O
diabetes    O
medicines    O
.    O

The    O
HbA1c    B-Assay100791527
was    O
examined    O
after    O
SGLT-2    O
inhibitors    O
were    O
given    O
alone    O
(    O
as    O
monotherapy    O
)    O
or    O
as    O
an    O
add    O
-    O
on    O
therapy    O
to    O
the    O
other    O
diabetes    O
medicines    O
.    O

The    O
HbA1c    B-Assay100791527
was    O
examined    O
after    O
SGLT-2    O
inhibitors    O
were    O
given    O
alone    O
(    O
as    O
monotherapy    O
)    O
or    O
as    O
an    O
add    O
-    O
on    O
therapy    O
to    O
the    O
other    O
diabetes    O
medicines    O
.    O

The    O
HbA1c    B-Assay100791527
was    O
examined    O
after    O
SGLT-2    O
inhibitors    O
were    O
given    O
alone    O
(    O
as    O
monotherapy    O
)    O
or    O
as    O
an    O
add    O
-    O
on    O
therapy    O
to    O
the    O
other    O
diabetes    O
medicines    O
.    O

The    O
HbA1c    B-Assay100791527
was    O
examined    O
after    O
SGLT-2    O
inhibitors    O
were    O
given    O
alone    O
(    O
as    O
monotherapy    O
)    O
or    O
as    O
an    O
add    O
-    O
on    O
therapy    O
to    O
the    O
other    O
diabetes    O
medicines    O
.    O

The    O
HbA1c    B-Assay100791527
was    O
examined    O
after    O
SGLT-2    O
inhibitors    O
were    O
given    O
alone    O
(    O
as    O
monotherapy    O
)    O
or    O
as    O
an    O
add    O
-    O
on    O
therapy    O
to    O
the    O
other    O
diabetes    O
medicines    O
.    O

The    O
HbA1c    B-Assay100791527
was    O
examined    O
after    O
SGLT-2    O
inhibitors    O
were    O
given    O
alone    O
(    O
as    O
monotherapy    O
)    O
or    O
as    O
an    O
add    O
-    O
on    O
therapy    O
to    O
the    O
other    O
diabetes    O
medicines    O
.    O

HbA1c    B-Assay100791527
:    O
0.20(0.061    O
)    O

After    O
52    O
weeks    O
,    O
patients    O
treated    O
with    O
insulin    O
degludec    O
produced    O
a    O
similar    O
reduction    O
in    O
HbA1c    B-Assay100791527
(    O
0.40%    O
vs.    O
0.39%    O
)    O
meeting    O
the    O
criteria    O
for    O
noninferiority    O
.    O

Evidence    O
supporting    O
the    O
binding    O
of    O
Cr3    O
+    O
to    O
transferrin    O
comes    O
from    O
extensive    O
clinical    O
studies    O
that    O
showed    O
a    O
positive    O
correlation    O
between    O
levels    O
of    O
ferritin    O
and    O
of    O
fasting    O
glucose    O
,    O
insulin    O
,    O
and    O
glycosylated    B-Assay100791527
hemoglobin    I-Assay100791527
(    O
Hb1Ac    O
)    O
levels    O
.    O

Although    O
the    O
authors    O
of    O
this    O
review    O
mentioned    O
that    O
chromium(III    O
)    O
picolinate    O
decreases    O
HbA1c    B-Assay100791527
levels    O
(    O
measure    O
of    O
plasma    O
glucose    O
concentration    O
)    O
by    O
0.7%    O
(    O
95%    O
CI    O
)    O
in    O
type    O
2    O
diabetes    O
patients    O
,    O
they    O
noted    O
that    O
most    O
poor    O
quality    O
studies    O
produced    O
larger    O
positive    O
outcomes    O
than    O
higher    O
quality    O
studies    O
.    O

Compared    O
to    O
Cr(III    O
)    O
species    O
,    O
metformin    O
performs    O
both    O
more    O
consistently    O
and    O
effectively    O
,    O
lowering    O
HbA1c    B-Assay100791527
by    O
1.12%    O
,    O
compared    O
to    O
0.6%    O
with    O
chromium(III    O
)    O
picolinate    O
(    O
although    O
data    O
for    O
it    O
is    O
weak    O
)    O
.    O

Switching    O
people    O
with    O
diabetes    O
to    O
a    O
vegan    O
diet    O
lowered    O
hemoglobin    B-Assay100791527
A1C    I-Assay100791527
and    O
LDL    O
levels    O
in    O
one    O
study    O
.    O

Biological    B-Assay100791527
terrain    I-Assay100791527
assessment    I-Assay100791527
–    O
a    O
set    O
of    O
computerized    O
tests    O
used    O
to    O
measure    O
the    O
pH    O
,    O
resistivity    O
,    O
and    O
redox    O
of    O
a    O
person    O
's    O
urine    O
,    O
blood    O
,    O
and    O
saliva    O
,    O
with    O
the    O
intention    O
of    O
recommending    O
a    O
customized    O
program    O
of    O
health    O
supplements    O
and    O
remedies    O
(    O
such    O
as    O
vitamins    O
,    O
homeopathic    O
supplements    O
,    O
or    O
herbal    O
medicines    O
)    O
based    O
on    O
the    O
results    O
.    O

C-reactive    B-Assay100791527
protein    I-Assay100791527
levels    O
in    O
the    O
blood    O
need    O
to    O
be    O
measured    O
every    O
few    O
days    O
in    O
order    O
to    O
have    O
enough    O
time    O
points    O
to    O
show    O
a    O
repeating    O
fluctuation    O
(    O
a    O
wave    O
-    O
like    O
cycle    O
)    O
.    O

Dr    O
Roxana    O
S.    O
Dronca    O
et    O
al    O
.    O
from    O
the    O
Mayo    O
Clinic    O
found    O
that    O
the    O
immune    O
cycle    O
is    O
also    O
evident    O
in    O
fluctuations    O
beyond    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
,    O
as    O
it    O
can    O
be    O
seen    O
in    O
"    O
infradian    O
immune    O
biorhythms    O
of    O
both    O
immune    O
cell    O
subpopulations    O
and    O
cytokines    O
.    O
"    O

Meta    O
analysis    O
on    O
cytokine    O
levels    O
in    O
depressed    O
patients    O
have    O
demonstrated    O
increased    O
levels    O
of    O
IL-1    O
,    O
IL-6    O
,    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
,    O
but    O
not    O
IL-10    O
in    O
depressed    O
patients    O
.    O

A    O
2017    O
study    O
found    O
CLA    O
supplementation    O
has    O
been    O
associated    O
with    O
an    O
increase    O
plasma    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
concentrations    O
and    O
a    O
reduction    O
in    O
serum    O
adiponectin    O
concentrations    O
,    O
which    O
indicates    O
that    O
CLA    O
supplements    O
have    O
a    O
pro    O
-    O
inflammatory    O
effect    O
.    O

Myocardial    O
inflammation    O
can    O
be    O
suspected    O
on    O
the    O
basis    O
of    O
electrocardiographic    O
(    O
ECG    O
)    O
results    O
,    O
elevated    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
(    O
CRP    O
)    O
and/or    O
erythrocyte    O
sedimentation    O
rate    O
(    O
ESR    O
)    O
,    O
and    O
increased    O
IgM    O
(    O
serology    O
)    O
against    O
viruses    O
known    O
to    O
affect    O
the    O
myocardium    O
.    O

Statin    O
use    O
in    O
those    O
with    O
psoriasis    O
and    O
hyperlipidemia    O
was    O
associated    O
with    O
decreased    O
levels    O
of    O
high-sensitivity    B-Assay100791527
C-reactive    I-Assay100791527
protein    I-Assay100791527
and    O
TNFα    O
as    O
well    O
as    O
decreased    O
activity    O
of    O
the    O
immune    O
protein    O
LFA-1    O
.    O

|rowspan=2|    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
(    O
CRP    O
)    O

It    O
is    O
known    O
that    O
monocytes    O
and    O
macrophages    O
also    O
produce    O
higher    O
levels    O
of    O
tumor    O
necrosis    O
factor    O
alpha    O
(    O
TNF-α    O
)    O
,    O
interleukin    O
6(IL-6    O
)    O
other    O
than    O
IL    O
-    O
Iβ    O
During    O
the    O
febrile    O
(    O
fever    O
)    O
attacks    O
and    O
during    O
the    O
attacks    O
the    O
C    O
-    O
reactive    O
protein    O
(    O
CRP    B-Assay100791527
)    O
also    O
increases    O
.    O
[    O
9    O
]    O
.    O

suPAR    O
levels    O
are    O
positively    O
correlated    O
with    O
pro    O
-    O
inflammatory    O
biomarkers    O
,    O
such    O
as    O
tumor    O
necrosis    O
factor-α    O
,    O
leukocyte    O
counts    O
,    O
and    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
.    O

C-reactive    B-Assay100791527
protein    I-Assay100791527
:    O
0.37(0.061    O
)    O

Relative    O
to    O
other    O
NSAIDs    O
,    O
salsalate    O
has    O
a    O
weak    O
inhibitory    O
effect    O
on    O
the    O
cyclooxygenase    O
enzyme    O
and    O
decreases    O
the    O
production    O
of    O
several    O
proinflammatory    O
chemical    O
signals    O
such    O
as    O
interleukin-6    O
,    O
TNF    O
-    O
alpha    O
,    O
and    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
.    O

A    O
2005    O
Cochrane    O
review    O
concluded    O
that    O
acupuncture    O
use    O
to    O
treat    O
rheumatoid    O
arthritis    O
"    O
has    O
no    O
effect    O
on    O
ESR    O
,    O
CRP    B-Assay100791527
,    O
pain    O
,    O
patient    O
's    O
global    O
assessment    O
,    O
number    O
of    O
swollen    O
joints    O
,    O
number    O
of    O
tender    O
joints    O
,    O
general    O
health    O
,    O
disease    O
activity    O
and    O
reduction    O
of    O
analgesics    O
.    O
"    O

Routine    O
blood    O
tests    O
show    O
features    O
of    O
acute    O
inflammation    O
(    O
raised    O
white    O
blood    O
cell    O
count    O
and    O
elevated    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
level    O
)    O
,    O
and    O
usually    O
abnormal    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
(    O
LFTs    O
)    O
.    O

The    O
"    O
short    O
"    O
pentraxins    O
include    O
Serum    O
Amyloid    O
P    O
component    O
(    O
SAP    O
)    O
and    O
C    B-Assay100791527
reactive    I-Assay100791527
protein    I-Assay100791527
(    O
CRP    O
)    O
.    O

C-reactive    B-Assay100791527
protein    I-Assay100791527
is    O
expressed    O
during    O
acute    O
phase    O
response    O
to    O
tissue    O
injury    O
or    O
inflammation    O
in    O
mammals    O
.    O

CRP    B-Assay100791527

Multivariate    O
analyses    O
showed    O
that    O
physician    O
-    O
recorded    O
obesity    O
on    O
admission    O
and    O
pulmonary    O
conditions    O
other    O
than    O
asthma    O
or    O
chronic    O
obstructive    O
pulmonary    O
disease    O
(    O
COPD    O
)    O
were    O
associated    O
with    O
a    O
severe    O
outcome    O
,    O
as    O
were    O
radiologically    O
confirmed    O
pneumonia    O
and    O
a    O
raised    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
(    O
CRP    O
)    O
level    O
(    O
≥.    O
59%    O
of    O
all    O
in    O
-    O
hospital    O
deaths    O
occurred    O
in    O
previously    O
healthy    O
people    O
.    O

In    O
the    O
case    O
that    O
the    O
cause    O
is    O
not    O
obvious    O
,    O
a    O
reasonable    O
initial    O
workup    O
would    O
include    O
a    O
complete    O
blood    O
count    O
,    O
urinalysis    O
,    O
basic    O
metabolic    O
panel    O
,    O
fecal    O
occult    O
blood    O
testing    O
,    O
erythrocyte    O
sedimentation    O
rate    O
(    O
ESR    O
)    O
,    O
and    O
C-reactive    B-Assay100791527
protein    I-Assay100791527
level    O
.    O

Blood    O
tests    O
may    O
show    O
an    O
elevation    O
of    O
the    O
ESR    O
and    O
CRP    B-Assay100791527
,    O
but    O
are    O
otherwise    O
unremarkable    O
.    O

Howell-Jolly    B-Assay100791527
body    I-Assay100791527

Howell–Jolly    B-Assay100791527
bodies    I-Assay100791527
are    O
histopathological    O
findings    O
of    O
basophilic    O
nuclear    O
remnants    O
(    O
clusters    O
of    O
DNA    O
)    O
in    O
circulating    O
erythrocytes    O
.    O

Expression    O
of    O
cyclins    O
in    O
individual    O
cells    O
in    O
relation    O
to    O
cellular    O
DNA    O
content    O
(    O
cell    O
cycle    O
phase    O
)    O
is    O
often    O
measured    O
by    O
flow    B-Assay100791527
cytometry    I-Assay100791527
.    O

1970    O
-    O
Leonard    O
Herzenberg    O
develops    O
the    O
fluorescence-activated    B-Assay100791527
cell    I-Assay100791527
sorter    I-Assay100791527
(FACS)    I-Assay100791527
which    O
revolutionizes    O
the    O
study    O
of    O
cancer    O
cells    O
and    O
will    O
be    O
essential    O
for    O
purification    O
of    O
adult    O
stem    O
cells    O

Leonard    O
Herzenberg    O
-    O
Winner    O
of    O
the    O
Kyoto    O
Prize    O
for    O
development    O
of    O
fluorescent-activated    B-Assay100791527
cell    I-Assay100791527
sorting    I-Assay100791527
.    O

Flow    B-Assay100791527
cytometry    I-Assay100791527

Cell    O
analysis    O
is    O
typically    O
done    O
by    O
flow    B-Assay100791527
cytometry    I-Assay100791527
and    O
can    O
be    O
implemented    O
into    O
microfluidics    O
with    O
lower    O
fluid    O
velocities    O
and    O
lower    O
throughput    O
than    O
their    O
conventional    O
macroscopic    O
counterparts    O
.    O

It    O
is    O
difficult    O
to    O
detect    O
without    O
flow    B-Assay100791527
cytometry    I-Assay100791527
,    O
because    O
normal    O
levels    O
are    O
so    O
low    O
.    O

Microscopy    O
and    O
Imaging    O
:    O
this    O
facility    O
contains    O
numerous    O
state    O
of    O
the    O
art    O
microscopes    O
and    O
flow    B-Assay100791527
cytometer    I-Assay100791527
instruments    O
.    O

Flow    B-Assay100791527
cytometry    I-Assay100791527
core    O
facility    O
(    O
used    O
in    O
many    O
universities    O
)    O

The    O
researcher    O
analyzed    O
it    O
by    O
the    O
cytoflow    B-Assay100791527
method    O
.    O

Several    O
FSL    O
constructs    O
have    O
been    O
used    O
to    O
label    O
viruses    O
to    O
assist    O
in    O
their    O
flow-cytometric    B-Assay100791527
visualisation    I-Assay100791527
and    O
to    O
track    O
them    O
real    O
time    O
distribution    O
in    O
animal    O
models    O
.    O

It    O
is    O
a    O
specialized    O
flow    B-Assay100791527
cytometer    I-Assay100791527
that    O
uses    O
high    O
-    O
sensitivity    O
fluorescence    O
detection    O
to    O
give    O
a    O
direct    O
measurement    O
of    O
the    O
concentration    O
of    O
virus    O
particles    O
in    O
a    O
fraction    O
of    O
the    O
time    O
required    O
for    O
traditional    O
plaque    O
assays    O
.    O

”    O
flow    B-Assay100791527
cytometer    I-Assay100791527
designed    O
exclusively    O
for    O
a    O
niche    O
application    O
,    O
in    O
this    O
case    O
virus    O
quantification    O
.    O

Foetal    O
-    O
maternal    O
haemorrhage    O
can    O
also    O
be    O
diagnosed    O
by    O
flow    B-Assay100791527
cytometry    I-Assay100791527
,    O
using    O
anti    O
-    O
foetal    O
hemoglobin    O
antibodies    O
(    O
anti    O
-    O
HbF    O
)    O
.    O

The    O
presence    O
of    O
lymphocytosis    O
in    O
an    O
elderly    O
individual    O
should    O
raise    O
strong    O
suspicion    O
for    O
CLL    O
,    O
and    O
a    O
confirmatory    O
diagnostic    O
test    O
,    O
in    O
particular    O
flow    B-Assay100791527
cytometry    I-Assay100791527
,    O
should    O
be    O
performed    O
unless    O
clinically    O
unnecessary    O
.    O

The    O
combination    O
of    O
the    O
microscopic    O
examination    O
of    O
the    O
peripheral    O
blood    O
and    O
analysis    O
of    O
the    O
lymphocytes    O
by    O
flow    B-Assay100791527
cytometry    I-Assay100791527
to    O
confirm    O
clonality    O
and    O
marker    O
molecule    O
expression    O
is    O
needed    O
to    O
establish    O
the    O
diagnosis    O
of    O
CLL    O
.    O

A    O
flow    B-Assay100791527
cytometer    I-Assay100791527
instrument    O
can    O
examine    O
the    O
expression    O
of    O
molecules    O
on    O
individual    O
cells    O
in    O
fluids    O
.    O

Fluorescein    O
isothiocyanate    O
(    O
FITC    O
)    O
is    O
a    O
derivative    O
of    O
fluorescein    O
used    O
in    O
wide    O
-    O
ranging    O
applications    O
including    O
flow    B-Assay100791527
cytometry    I-Assay100791527
.    O

Studies    O
rely    O
almost    O
exclusively    O
on    O
Flow    B-Assay100791527
cytometry    I-Assay100791527
and    O
fluorescence    O
activated    O
cell    O
sorting    O
(    O
FACS    O
)    O
analysis    O
,    O
which    O
gives    O
no    O
information    O
about    O
cell    O
lineage    O
or    O
behaviour    O
.    O

The    O
labelled    O
cells    O
are    O
processed    O
in    O
a    O
flow    B-Assay100791527
cytometer    I-Assay100791527
,    O
a    O
laser    O
-    O
based    O
instrument    O
capable    O
of    O
analyzing    O
thousands    O
of    O
cells    O
per    O
second    O
.    O

The    O
IEBA    O
technology    O
can    O
be    O
used    O
with    O
existing    O
bioassays    O
protocols    O
(    O
particularly    O
the    O
bioassays    O
on    O
beads    O
)    O
,    O
and    O
readers    O
without    O
the    O
need    O
to    O
invest    O
in    O
a    O
flow    B-Assay100791527
cytometer    I-Assay100791527
or    O
other    O
capital    O
-    O
intensive    O
devices    O
to    O
read    O
it    O
out    O
.    O

One    O
study    O
which    O
did    O
address    O
this    O
topic    O
used    O
flow    B-Assay100791527
cytometry    I-Assay100791527
or    O
elutriation    O
of    O
synchronized    O
cells    O
treated    O
with    O
actinomycin    O
D1    O
,    O
camptothecin    O
,    O
or    O
aphidicolin    O
,    O
each    O
of    O
which    O
had    O
been    O
documented    O
to    O
exert    O
its    O
effects    O
in    O
a    O
particular    O
phase    O
of    O
the    O
cell    O
cycle    O
.    O

"    O
O.    O
tauri    O
"    O
was    O
discovered    O
in    O
1994    O
in    O
the    O
Thau    O
lagoon    O
,    O
France    O
,    O
in    O
a    O
year    O
-    O
long    O
study    O
of    O
the    O
picoplankton    O
population    O
of    O
the    O
lagoon    O
using    O
flow    B-Assay100791527
cytometry    I-Assay100791527
.    O
"    O

Flow    B-Assay100791527
cytometry    I-Assay100791527
testing    O
is    O
performed    O
regularly    O
in    O
people    O
with    O
previous    O
aplastic    O
anemia    O
to    O
monitor    O
for    O
the    O
development    O
of    O
PNH    O
.    O

At    O
first    O
,    O
EuroFlow    O
was    O
composed    O
of    O
18    O
diagnostic    O
research    O
groups    O
and    O
two    O
SMEs    O
(    O
small    O
/    O
medium    O
enterprises    O
)    O
from    O
eight    O
different    O
European    O
countries    O
with    O
complementary    O
knowledge    O
and    O
skills    O
in    O
the    O
field    O
of    O
flow    B-Assay100791527
cytometry    I-Assay100791527
and    O
immunophenotyping    O
.    O

In    O
flow    B-Assay100791527
cytometry    I-Assay100791527
,    O
CD23    O
is    O
helpful    O
in    O
the    O
differentiation    O
of    O
chronic    O
lymphocytic    O
leukemia    O
(    O
CD23-positive    O
)    O
from    O
mantle    O
cell    O
lymphoma    O
(    O
CD23-negative    O
)    O
.    O

Human    O
lymphocyte    O
cultures    O
may    O
be    O
analyzed    O
by    O
flow    B-Assay100791527
cytometry    I-Assay100791527
to    O
assess    O
chromosomal    O
abnormalities    O
,    O
such    O
as    O
polyploidy    O
,    O
hypodiploidy    O
,    O
and    O
hyperdiploidy    O
.    O

Current    O
protocols    O
include    O
magnetic    O
-    O
activated    O
cell    O
sorting    O
(    O
MACS    O
)    O
and    O
fluorescence-activated    B-Assay100791527
cell    I-Assay100791527
sorting    I-Assay100791527
(    O
FACS    O
)    O
based    O
on    O
positive    O
SSC    O
cellular    O
markers    O
such    O
as    O
CD90    O
and    O
FGFR3    O
in    O
combination    O
with    O
negative    O
markers    O
like    O
CD45    O
.    O

Antibodies    O
are    O
used    O
in    O
flow    B-Assay100791527
cytometry    I-Assay100791527
to    O
differentiate    O
cell    O
types    O
by    O
the    O
proteins    O
they    O
express    O
;    O
different    O
types    O
of    O
cell    O
express    O
different    O
combinations    O
of    O
cluster    O
of    O
differentiation    O
molecules    O
on    O
their    O
surface    O
,    O
and    O
produce    O
different    O
intracellular    O
and    O
secretable    O
proteins    O
.    O

Fluorescent-activated    B-Assay100791527
cell    I-Assay100791527
sorting    I-Assay100791527
–    O
Specialized    O
type    O
of    O
flow    O
cytometry    O
.    O

An    O
example    O
of    O
a    O
cellular    O
biomarker    O
sorting    O
technique    O
is    O
Fluorescent-activated    B-Assay100791527
cell    I-Assay100791527
sorting    I-Assay100791527
.    O

Flow    B-Assay100791527
cytometry    I-Assay100791527

Microscopic    O
viewing    O
of    O
the    O
red    O
blood    O
cells    O
will    O
reveal    O
marked    O
unequal    B-Assay100791527
cell    I-Assay100791527
size    I-Assay100791527
and    O
abnormal    B-Assay100791527
cell    I-Assay100791527
shape    I-Assay100791527
.    O

Hypo-osmolality    B-Assay100791527
and    O
hyponatraemia    O

|    O
Osmolality    B-Assay100791527

The    O
monospot    B-Assay100791527
test    O
is    O
not    O
recommended    O
for    O
general    O
use    O
by    O
the    O
CDC    O
due    O
to    O
its    O
poor    O
accuracy    O
.    O

Abderhalden    B-Assay100791527
reaction    I-Assay100791527
,    O
developed    O
by    O
Emil    O
Abderhalden    O

Enzyme    B-Assay100791527
multiplied    I-Assay100791527
immunoassay    I-Assay100791527
technique    I-Assay100791527
(    O
EMIT    B-Assay100791527
)    O
is    O
a    O
common    O
method    O
for    O
qualitative    O
and    O
quantitative    O
determination    O
of    O
therapeutic    O
and    O
recreational    O
drugs    O
and    O
certain    O
proteins    O
in    O
serum    O
and    O
urine    O
.    O

Since    O
the    O
test    O
is    O
only    O
a    O
qualitative    O
determination    O
of    O
the    O
presence    O
of    O
fetal    O
hemoglobin    O
in    O
maternal    O
blood    O
,    O
the    O
quantitative    O
Kleihauer-Betke    B-Assay100791527
test    I-Assay100791527
is    O
more    O
commonly    O
used    O
.    O

Kleihauer-Betke    B-Assay100791527
test    I-Assay100791527

|    O
Serum    B-Assay100791527
free    I-Assay100791527
light    I-Assay100791527
chain    I-Assay100791527
(    O
FLC    O
)    O
:    O
kappa    O
/    O
lambda    O
ratio    O

For    O
example    O
the    O
total    O
levels    O
of    O
antibodies    O
isotypes    O
or    O
classes    O
:    O
Immunoglobulin    O
M    O
,    O
Immunoglobulin    O
G    O
,    O
and    O
Immunoglobulin    O
A.    O
It    O
is    O
important    O
in    O
quantification    O
of    O
free    B-Assay100791527
light    I-Assay100791527
chains    I-Assay100791527
in    O
diseases    O
such    O
as    O
multiple    O
myeloma    O
.    O

Tetracosactide    O
stimulates    O
the    O
release    O
of    O
corticosteroids    O
such    O
as    O
cortisol    O
from    O
the    O
adrenal    O
glands    O
,    O
and    O
is    O
used    O
for    O
the    O
ACTH    B-Assay100791527
stimulation    I-Assay100791527
test    I-Assay100791527
to    O
assess    O
adrenal    O
gland    O
function    O
.    O

Both    O
versions    O
of    O
the    O
hormone    O
are    O
also    O
used    O
to    O
perform    O
the    O
ACTH    B-Assay100791527
stimulation    I-Assay100791527
test    I-Assay100791527
to    O
diagnose    O
hypoadrenocorticism    O
in    O
dogs    O
and    O
sometimes    O
cats    O
.    O

ACTH    B-Assay100791527
stimulation    I-Assay100791527
test    I-Assay100791527

In    O
agreement    O
with    O
these    O
results    O
,    O
a    O
subsequent    O
clinical    O
trial    O
found    O
that    O
21    O
G    O
,    O
23    O
G    O
,    O
and    O
25    O
G    O
butterflies    O
connected    O
directly    O
to    O
vacuum    O
tubes    O
caused    O
the    O
same    O
amount    O
of    O
hemolysis    O
and    O
gave    O
the    O
same    O
coagulation    B-Assay100791527
panel    I-Assay100791527
test    O
results    O
.    O

Trichoscopy    B-Assay100791527
is    O
a    O
method    O
of    O
hair    O
and    O
scalp    O
evaluation    O
and    O
is    O
used    O
for    O
diagnosing    O
hair    O
and    O
scalp    O
diseases    O
.    O

She    O
is    O
the    O
author    O
of    O
"    O
Dermoscopy    O
of    O
Hair    O
and    O
Scalp    O
Disorders    O
"    O
,    O
the    O
first    O
hair    O
and    O
scalp    O
dermoscopy    O
(    O
trichoscopy    B-Assay100791527
)    O
atlas    O
ever    O
published    O
.    O

---    O
radioallergosorbent    B-Assay100791527
test    I-Assay100791527

Even    O
if    O
a    O
person    O
has    O
negative    O
skin-prick,    B-Assay100791527
intradermal    I-Assay100791527
and    O
blood    B-Assay100791527
tests    I-Assay100791527
for    O
allergies    O
,    O
they    O
may    O
still    O
have    O
allergic    O
rhinitis    O
,    O
from    O
a    O
local    O
allergy    O
in    O
the    O
nose    O
.    O

Several    O
serological    O
tests    O
can    O
be    O
performed    O
to    O
assess    O
total    O
IgE    O
and    O
allergen    O
specific    O
IgE    O
and    O
IgG    O
:    O
ELISA    O
,    O
MAST    O
,    O
HIA    O
,    O
and    O
CAP    B-Assay100791527
RAST    I-Assay100791527
.    O

Hair    B-Assay100791527
perforation    I-Assay100791527
test    I-Assay100791527

Fecal    B-Assay100791527
occult    I-Assay100791527
blood    I-Assay100791527

The    O
stool    B-Assay100791527
guaiac    I-Assay100791527
test    I-Assay100791527
or    O
guaiac    B-Assay100791527
fecal    I-Assay100791527
occult    I-Assay100791527
blood    I-Assay100791527
test    I-Assay100791527
(    O
gFOBT    B-Assay100791527
)    O
is    O
one    O
of    O
several    O
methods    O
that    O
detects    O
the    O
presence    O
of    O
fecal    B-Assay100791527
occult    I-Assay100791527
blood    I-Assay100791527
(    O
blood    O
invisible    O
in    O
the    O
feces    O
)    O
.    O

The    O
article    O
fecal    B-Assay100791527
occult    I-Assay100791527
blood    I-Assay100791527
(    O
FOB    O
)    O
provides    O
an    O
expanded    O
consideration    O
of    O
the    O
clinical    O
application    O
of    O
FOB    O
tests    O
generally    O
,    O
including    O
other    O
clinical    O
methods    O
,    O
and    O
the    O
comments    O
here    O
are    O
those    O
that    O
relate    O
specifically    O
to    O
the    O
guaiac    O
gFOBT    O
method    O
.    O

When    O
they    O
occur    O
,    O
symptoms    O
include    O
rectal    B-Assay100791527
bleeding    I-Assay100791527
,    O
bloody    O
stools    O
,    O
abdominal    O
pain    O
and    O
fatigue    O
.    O

Colorectal    O
polyps    O
can    O
be    O
detected    O
using    O
a    O
faecal    B-Assay100791527
occult    I-Assay100791527
blood    I-Assay100791527
test    O
,    O
flexible    O
sigmoidoscopy    O
,    O
colonoscopy    O
,    O
virtual    O
colonoscopy    O
,    O
digital    O
rectal    O
examination    O
,    O
barium    O
enema    O
or    O
a    O
pill    O
camera    O
.    O

Tomaso    O
Casoni    O
(    O
1880–1933    O
)    O
was    O
an    O
Italian    O
physician    O
remembered    O
for    O
describing    O
the    O
Casoni    B-Assay100791527
test    I-Assay100791527
for    O
the    O
diagnosis    O
of    O
hydatid    O
disease    O
.    O

Examination    O
of    O
a    O
stained    O
blood    B-Assay100791527
smear    I-Assay100791527
using    O
a    O
microscope    O
can    O
also    O
be    O
helpful    O
,    O
and    O
it    O
is    O
sometimes    O
a    O
necessity    O
in    O
regions    O
of    O
the    O
world    O
where    O
automated    O
analysis    O
is    O
less    O
accessible    O
.    O

Clinical    O
signs    O
of    O
loss    O
or    O
destruction    O
include    O
abnormal    O
peripheral    B-Assay100791527
blood    I-Assay100791527
smear    I-Assay100791527
with    O
signs    O
of    O
hemolysis    O
;    O
elevated    O
LDH    O
suggesting    O
cell    O
destruction    O
;    O
or    O
clinical    O
signs    O
of    O
bleeding    O
,    O
such    O
as    O
guaiac    O
-    O
positive    O
stool    O
,    O
radiographic    O
findings    O
,    O
or    O
frank    O
bleeding    O
.    O

"    O
Klein    O
-    O
Gumprecht    O
shadow    O
nuclei    O
"    O
:    O
Shadow    O
nuclei    O
observed    O
in    O
the    O
peripheral    O
blood    B-Assay100791527
smear    I-Assay100791527
of    O
patients    O
with    O
leukemia    O
.    O

It    O
can    O
be    O
run    O
on    O
its    O
own    O
,    O
or    O
connected    O
to    O
a    O
blood    B-Assay100791527
film    I-Assay100791527
making    O
and    O
staining    O
unit    O
.    O

Complete    O
blood    O
count    O
and    O
reticulocyte    O
count    O
;    O
in    O
active    O
G6PD    O
deficiency    O
,    O
Heinz    B-Assay100791527
bodies    I-Assay100791527
can    O
be    O
seen    O
in    O
red    O
blood    O
cells    O
on    O
a    O
blood    B-Assay100791527
film    I-Assay100791527
;    O

Definitive    O
diagnosis    O
relies    O
on    O
the    O
observation    O
of    O
the    O
organism    O
in    O
blood    B-Assay100791527
smear    I-Assay100791527
.    O

HELLP    O
is    O
characterized    O
by    O
hemolysis    O
on    O
peripheral    B-Assay100791527
blood    I-Assay100791527
smear    I-Assay100791527
with    O
serum    O
lactate    O
dehydrogenase    O
>    O
600    O
IU    O
/    O
l    O
;    O
serum    O
aspartate    O
aminotransferase    O
>    O
70    O
IU    O
/    O
l    O
;    O
and    O
platelet    O
count    O
50,000    O
and    O
≤100,000    O
cells/μl    O
,    O
and    O
class    O
3    O
HELLP    O
syndrome    O
featured    O
mild    O
thrombocytopenia    O
with    O
a    O
platelet    O
nadir    O
between    O
>    O
100,000    O
and    O
≤150,000    O
cells/μl    O
.    O
"    O

The    O
blood    B-Assay100791527
film    I-Assay100791527
can    O
point    O
towards    O
vitamin    O
deficiency    O
:    O

Pyknocytes    O
are    O
red    O
blood    O
cells    O
that    O
appear    O
distorted    O
,    O
irregular    O
and    O
small    O
with    O
abnormal    O
projections    O
and    O
would    O
typically    O
be    O
identified    O
by    O
a    O
pathologist    O
on    O
a    O
peripheral    O
blood    B-Assay100791527
smear    I-Assay100791527
.    O

A    O
standard    O
blood    B-Assay100791527
smear    I-Assay100791527
is    O
prepared    O
from    O
the    O
mother    O
's    O
blood    O
,    O
and    O
exposed    O
to    O
an    O
acid    O
bath    O
.    O

On    O
a    O
stained    O
blood    B-Assay100791527
smear    I-Assay100791527
,    O
platelets    O
appear    O
as    O
dark    O
purple    O
spots    O
,    O
about    O
20%    O
the    O
diameter    O
of    O
red    O
blood    O
cells    O
.    O

Uncommonly    O
,    O
a    O
diagnosis    O
can    O
be    O
made    O
by    O
looking    O
under    O
a    O
microscope    O
at    O
a    O
blood    B-Assay100791527
smear    I-Assay100791527
for    O
the    O
presence    O
of    O
the    O
"    O
ehrlichia    O
"    O
morulae    O
,    O
which    O
sometimes    O
can    O
be    O
seen    O
as    O
intracytoplasmic    O
inclusion    O
bodies    O
within    O
a    O
white    O
blood    O
cell    O
.    O

Specifically    O
prothrombin    B-Assay100791527
time    I-Assay100791527
(    O
PT    O
)    O
or    O
activated    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
)    O
are    O
prolonged    O
.    O

They    O
should    O
include    O
a    O
full    O
blood    O
count    O
,    O
blood    B-Assay100791527
urea    I-Assay100791527
nitrogen    I-Assay100791527
(    O
BUN    O
)    O
,    O
creatinine    O
,    O
and    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
such    O
as    O
albumin    O
,    O
international    B-Assay100791527
normalized    I-Assay100791527
ratio    I-Assay100791527
(    O
INR    O
)    O
,    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
(    O
PTT    O
)    O
,    O
serum    O
amylase    O
and    O
total    O
bilirubin    O
(    O
TBIL    O
)    O
.    O

aPTT    B-Assay100791527
(    O
Activated    O
Partial    O
Thromboplastin    O
time    O
)    O
for    O
the    O
contact    O
activation    O
pathway    O
(    O
intrinsic    O
pathway    O
)    O

It    O
is    O
usually    O
ordered    O
in    O
situations    O
where    O
the    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
(    O
PTT    O
)    O
test    O
may    O
take    O
an    O
excessive    O
amount    O
of    O
time    O
to    O
process    O
or    O
is    O
not    O
clinically    O
useful    O
.    O

Possible    O
non    O
-    O
specific    O
laboratory    O
indicators    O
of    O
EVD    O
include    O
a    O
low    O
platelet    O
count    O
;    O
an    O
initially    O
decreased    O
white    O
blood    O
cell    O
count    O
followed    O
by    O
an    O
increased    O
white    O
blood    O
cell    O
count    O
;    O
elevated    O
levels    O
of    O
the    O
liver    O
enzymes    O
alanine    O
aminotransferase    O
(    O
ALT    O
)    O
and    O
aspartate    O
aminotransferase    O
(    O
AST    O
)    O
;    O
and    O
abnormalities    O
in    O
blood    O
clotting    O
often    O
consistent    O
with    O
disseminated    O
intravascular    O
coagulation    O
(    O
DIC    O
)    O
such    O
as    O
a    O
prolonged    O
prothrombin    B-Assay100791527
time    I-Assay100791527
,    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
,    O
and    O
bleeding    B-Assay100791527
time    I-Assay100791527
.    O

|    O
Activated    B-Assay100791527
partial    I-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
(    O
APTT    O
)    O

It    O
is    O
monitored    O
by    O
PTT    B-Assay100791527
.    O

Prolonged    O
activated    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527

Granulocytosis    B-Assay100791527

A    O
fecal    B-Assay100791527
pH    I-Assay100791527
test    I-Assay100791527
may    O
be    O
used    O
to    O
determine    O
lactose    O
intolerance    O
or    O
the    O
presence    O
of    O
an    O
infection    O
.    O

Insulin    B-Assay100791527
tolerance    I-Assay100791527
test    I-Assay100791527

The    O
ristocetin-induced    B-Assay100791527
platelet    I-Assay100791527
aggregation    I-Assay100791527
(    O
RIPA    B-Assay100791527
)    O
is    O
an    O
ex    O
vivo    O
assay    O
for    O
live    O
platelet    O
function    O
.    O

That    O
being    O
the    O
case    O
,    O
the    O
criteria    O
have    O
been    O
reassessed    O
,    O
such    O
as    O
onset    O
of    O
symptoms    O
,    O
prothrombin    B-Assay100791527
time    I-Assay100791527
(    O
PTT    O
)    O
,    O
serum    O
bilirubin    O
,    O
and    O
presence    O
of    O
encephalopathy    O
,    O
for    O
determining    O
at    O
what    O
point    O
a    O
transplant    O
becomes    O
necessary    O
for    O
survival    O
.    O

If    O
the    O
liver    O
damage    O
is    O
significant    O
,    O
albumin    O
may    O
be    O
decreased    O
due    O
to    O
an    O
inability    O
of    O
damaged    O
liver    O
cells    O
to    O
produce    O
this    O
protein    O
;    O
likewise    O
,    O
the    O
prothrombin    B-Assay100791527
time    I-Assay100791527
(    O
a    O
test    O
of    O
coagulation    O
)    O
may    O
be    O
prolonged    O
as    O
the    O
liver    O
is    O
unable    O
to    O
produce    O
proteins    O
known    O
as    O
clotting    O
factors    O
.    O

LMWH    O
therapy    O
does    O
not    O
affect    O
the    O
prothrombin    B-Assay100791527
time    I-Assay100791527
(    O
PT    O
)    O
or    O
the    O
INR    B-Assay100791527
,    O
and    O
anti    O
-    O
Xa    O
levels    O
are    O
not    O
reliable    O
.    O

Factors    O
that    O
were    O
associated    O
with    O
increased    O
6-month    O
survival    O
included    O
younger    O
age    O
,    O
shorter    O
prothrombin    B-Assay100791527
time    I-Assay100791527
,    O
lower    O
levels    O
of    O
bilirubin    O
in    O
baseline    O
studies    O
,    O
and    O
decrease    O
in    O
bilirubin    O
on    O
day    O
14    O
,    O
all    O
(    O
P<0.001    O
)    O
.    O

Specifically    O
prothrombin    B-Assay100791527
time    I-Assay100791527
(    O
PT    O
)    O
or    O
activated    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
)    O
are    O
prolonged    O
.    O

They    O
should    O
include    O
a    O
full    O
blood    O
count    O
,    O
blood    B-Assay100791527
urea    I-Assay100791527
nitrogen    I-Assay100791527
(    O
BUN    O
)    O
,    O
creatinine    O
,    O
and    O
liver    B-Assay100791527
function    I-Assay100791527
tests    I-Assay100791527
such    O
as    O
albumin    O
,    O
international    B-Assay100791527
normalized    I-Assay100791527
ratio    I-Assay100791527
(    O
INR    O
)    O
,    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
(    O
PTT    O
)    O
,    O
serum    O
amylase    O
and    O
total    O
bilirubin    O
(    O
TBIL    O
)    O
.    O

This    O
gives    O
a    O
reading    O
of    O
their    O
international    B-Assay100791527
normalised    I-Assay100791527
ratio    I-Assay100791527
,    O
a    O
measure    O
of    O
how    O
quickly    O
blood    O
clots    O
–    O
which    O
they    O
can    O
share    O
with    O
clinic    O
staff    O
via    O
an    O
automated    O
phone    O
call    O
.    O

Possible    O
non    O
-    O
specific    O
laboratory    O
indicators    O
of    O
EVD    O
include    O
a    O
low    O
platelet    O
count    O
;    O
an    O
initially    O
decreased    O
white    O
blood    O
cell    O
count    O
followed    O
by    O
an    O
increased    O
white    O
blood    O
cell    O
count    O
;    O
elevated    O
levels    O
of    O
the    O
liver    O
enzymes    O
alanine    O
aminotransferase    O
(    O
ALT    O
)    O
and    O
aspartate    O
aminotransferase    O
(    O
AST    O
)    O
;    O
and    O
abnormalities    O
in    O
blood    O
clotting    O
often    O
consistent    O
with    O
disseminated    O
intravascular    O
coagulation    O
(    O
DIC    O
)    O
such    O
as    O
a    O
prolonged    O
prothrombin    B-Assay100791527
time    I-Assay100791527
,    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
,    O
and    O
bleeding    B-Assay100791527
time    I-Assay100791527
.    O

|    O
Prothrombin    B-Assay100791527
time    I-Assay100791527
(    O
PT    O
)    O

|    O
INR    B-Assay100791527

In    O
2006    O
the    O
company    O
expanded    O
its    O
premises    O
and    O
undertook    O
a    O
clinical    O
trial    O
for    O
PT/INR    B-Assay100791527
with    O
the    O
Royal    O
London    O
Hospital    O
,    O
which    O
gave    O
excellent    O
results    O
in    O
comparison    O
with    O
a    O
universally    O
recognised    O
laboratory    O
-    O
based    O
industry    O
standard    O
.    O

If    O
warfarin    O
is    O
chosen    O
as    O
the    O
long    O
term    O
anticoagulant    O
,    O
this    O
poses    O
particular    O
challenges    O
due    O
to    O
the    O
falsely    O
elevated    O
prothrombin    B-Assay100791527
time    I-Assay100791527
and    O
INR    B-Assay100791527
caused    O
by    O
argatroban    O
.    O

MELD    O
uses    O
the    O
patient    O
's    O
values    O
for    O
serum    O
bilirubin    O
,    O
serum    O
creatinine    O
,    O
and    O
the    O
international    B-Assay100791527
normalized    I-Assay100791527
ratio    I-Assay100791527
for    I-Assay100791527
prothrombin    I-Assay100791527
time    I-Assay100791527
(INR)    I-Assay100791527
to    O
predict    O
survival    O
.    O

Certain    O
treatments    O
may    O
be    O
unsafe    O
if    O
blood    O
clotting    O
is    O
impaired    O
,    O
as    O
the    O
risk    O
of    O
bleeding    O
(    O
especially    O
from    O
sphincterotomy    O
)    O
is    O
increased    O
in    O
the    O
use    O
of    O
medication    O
such    O
as    O
clopidogrel    O
(    O
which    O
inhibits    O
platelet    O
aggregation    O
)    O
or    O
if    O
the    O
prothrombin    B-Assay100791527
time    I-Assay100791527
is    O
significantly    O
prolonged    O
.    O

Direct    B-Assay100791527
agglutination    I-Assay100791527
test    I-Assay100791527
,    O
any    O
test    O
that    O
uses    O
whole    O
organisms    O
as    O
a    O
means    O
of    O
looking    O
for    O
serum    O
antibody    O

captopril    B-Assay100791527
challenge    I-Assay100791527
test    I-Assay100791527

This    O
can    O
be    O
done    O
by    O
virus    O
isolation    O
in    O
cell    O
cultures    O
,    O
nucleic    O
acid    O
detection    O
by    O
PCR    O
,    O
viral    O
antigen    O
detection    O
(    O
such    O
as    O
for    O
NS1    B-Assay100791527
)    O
or    O
specific    O
antibodies    O
(    O
serology    O
)    O
.    O

---    O
fluorescent    B-Assay100791527
treponemal    I-Assay100791527
antibody    I-Assay100791527
absorption    I-Assay100791527
test    I-Assay100791527

Red    B-Assay100791527
blood    I-Assay100791527
cell    I-Assay100791527
indices    I-Assay100791527

Errol    O
Denton    O
,    O
fined    O
£    O
1,000    O
for    O
each    O
of    O
9    O
offences    O
,    O
with    O
costs    O
of    O
£    O
9,821    O
and    O
a    O
victim    O
surcharge    O
of    O
£    O
100    O
in    O
March    O
2014    O
for    O
claiming    O
that    O
live    B-Assay100791527
blood    I-Assay100791527
analysis    I-Assay100791527
,    O
lifestyle    O
changes    O
and    O
herbs    O
could    O
cure    O
cancer    O
–    O
case    O
brought    O
by    O
Westminster    O
Trading    O
Standards    O
.    O

Live    B-Assay100791527
blood    I-Assay100791527
analysis    I-Assay100791527

#    O
The    O
branched    O
DNA    O
(    O
bDNA    B-Assay100791527
)    O
method    O
can    O
use    O
either    O
DNA    O
or    O
RNA    O
as    O
the    O
target    O
nucleic    O
acid    O
.    O

As    O
a    O
result    O
,    O
it    O
can    O
be    O
used    O
for    O
people    O
with    O
either    O
type-1    O
or    O
type-2    O
diabetes    O
mellitus    O
to    O
identify    O
glycemic    O
variability    O
or    O
a    O
history    O
of    O
high    O
blood    O
glucose    O
even    O
if    O
current    O
glycemic    O
measurements    O
such    O
as    O
hemoglobin    B-Assay100791527
A1c    I-Assay100791527
(    O
HbA1c    O
)    O
and    O
blood    B-Assay100791527
glucose    I-Assay100791527
monitoring    I-Assay100791527
have    O
near    O
normal    O
values    O
.    O

In    O
2006    O
,    O
1,5-AG    O
showed    O
its    O
most    O
compelling    O
clinical    O
use    O
when    O
it    O
was    O
demonstrated    O
that    O
an    O
assay    O
(    O
GlycoMark    O
,    O
developed    O
by    O
Nippon    O
Kayaku    O
,    O
Inc.    O
)    O
for    O
postprandial    O
hyperglycemia    O
was    O
able    O
to    O
differentiate    O
two    O
patients    O
who    O
had    O
similar    O
,    O
near    O
goal    O
,    O
hemoglobin    O
A1c    O
values    O
,    O
yet    O
very    O
different    O
glucose    O
profiles    O
as    O
shown    O
by    O
continuous    O
blood    B-Assay100791527
glucose    I-Assay100791527
monitoring    I-Assay100791527
-    O
one    O
of    O
the    O
patients    O
having    O
excessive    O
glycemic    O
variability    O
.    O

Measures    O
will    O
include    O
fasting    O
insulin    O
,    O
HOMA2-IR    O
,    O
indices    O
from    O
continuous    B-Assay100791527
glucose    I-Assay100791527
monitoring    I-Assay100791527
and    O
the    O
behaviour    O
of    O
glucose    O
,    O
insulin    O
,    O
C    O
-    O
peptide    O
and    O
the    O
insulinogenic    O
index    O
during    O
the    O
course    O
of    O
a    O
mixed    O
meal    O
tolerance    O
test(duration    O
four    O
months    O
)    O
.    O

An    O
insulin    O
pump    O
is    O
an    O
alternative    O
to    O
multiple    O
daily    O
injections    O
of    O
insulin    O
by    O
insulin    O
syringes    O
or    O
an    O
insulin    O
pen    O
and    O
allows    O
for    O
intensive    O
insulin    O
therapy    O
when    O
used    O
in    O
conjunction    O
with    O
blood    B-Assay100791527
glucose    I-Assay100791527
monitoring    I-Assay100791527
and    O
carb    O
counting    O
.    O

Improvements    O
in    O
blood    B-Assay100791527
glucose    I-Assay100791527
monitoring    I-Assay100791527
.    O

To    O
achieve    O
the    O
best    O
balance    O
of    O
blood    O
sugar    O
with    O
either    O
intensive    O
/    O
flexible    O
method    O
,    O
a    O
patient    O
must    O
check    O
his    O
or    O
her    O
glucose    O
level    O
with    O
a    O
meter    O
monitoring    B-Assay100791527
of    I-Assay100791527
blood    I-Assay100791527
glucose    I-Assay100791527
several    O
times    O
a    O
day    O
.    O

The    O
captopril    B-Assay100791527
suppression    I-Assay100791527
test    I-Assay100791527
(    O
CST    B-Assay100791527
)    O
is    O
a    O
non    O
-    O
invasive    O
medical    O
test    O
that    O
measures    O
plasma    O
levels    O
of    O
aldosterone    O
.    O

#    O
Viscoelastic    O
measurements    O
e.g.    O
viscometry    O
,    O
elastography    O
(    O
e.g.    O
thromboelastography    B-Assay100791527
)    O

Other    O
tests    O
should    O
be    O
performed    O
to    O
get    O
a    O
baseline    O
measurement    O
of    O
their    O
current    O
blood    O
chemistry    O
,    O
such    O
as    O
a    O
arterial    O
blood    O
gas    O
or    O
thromboelastography    B-Assay100791527
.    O

Checkpoint    B-Assay100791527
was    O
the    O
name    O
of    O
the    O
first    O
rapid    O
HIV    B-Assay100791527
test    I-Assay100791527
facility    O
in    O
the    O
Netherlands    O
.    O

Gain    O
of    O
thyroid    O
,    O
or    O
Secretory    B-Assay100791527
capacity    I-Assay100791527
of    I-Assay100791527
the    I-Assay100791527
thyroid    I-Assay100791527
gland    I-Assay100791527
,    O
a    O
calculated    O
parameter    O
for    O
diagnosis    O
of    O
thyroid    O
disorders    O

It    O
is    O
important    O
to    O
maintain    O
normal    O
iron    B-Assay100791527
levels    I-Assay100791527
,    O
blood    O
pressure    O
levels    O
,    O
fluid    O
balance    O
,    O
adequate    O
total    O
energy    O
intake    O
,    O
and    O
normal    O
glycogen    O
levels    O
.    O

|rowspan=2|    O
Total    O
serum    B-Assay100791527
iron    I-Assay100791527
(    O
TSI    O
)    O
-    O
male    O

Serum    B-Assay100791527
iron    I-Assay100791527
,    O
percentage    O
saturation    O
and    O
ferritin    O
are    O
increased    O
.    O

Other    O
:    O
TCT    B-Assay100791527
,    O
bleeding    B-Assay100791527
time    I-Assay100791527
,    O
mixing    B-Assay100791527
test    I-Assay100791527
(    O
whether    O
an    O
abnormality    O
corrects    O
if    O
the    O
patient    O
's    O
plasma    O
is    O
mixed    O
with    O
normal    O
plasma    O
)    O
,    O
coagulation    O
factor    O
assays    O
,    O
antiphospholipid    O
antibodies    O
,    O
D-dimer    B-Assay100791527
,    O
genetic    O
tests    O
(    O
e.g.    O
factor    O
V    O
Leiden    O
,    O
prothrombin    O
mutation    O
G20210A    O
)    O
,    O
dilute    B-Assay100791527
Russell's    I-Assay100791527
viper    I-Assay100791527
venom    I-Assay100791527
time    I-Assay100791527
(    O
dRVVT    O
)    O
,    O
miscellaneous    O
platelet    O
function    O
tests    O
,    O
thromboelastography    B-Assay100791527
(    O
TEG    O
or    O
Sonoclot    O
)    O
,    O
euglobulin    B-Assay100791527
lysis    I-Assay100791527
time    I-Assay100791527
(    O
ELT    O
)    O
.    O

Heinz    B-Assay100791527
bodies    I-Assay100791527
form    O
in    O
the    O
cytoplasm    O
of    O
RBCs    O
and    O
appear    O
as    O
small    O
dark    O
dots    O
under    O
the    O
microscope    O
.    O

Complete    O
blood    O
count    O
and    O
reticulocyte    O
count    O
;    O
in    O
active    O
G6PD    O
deficiency    O
,    O
Heinz    B-Assay100791527
bodies    I-Assay100791527
can    O
be    O
seen    O
in    O
red    O
blood    O
cells    O
on    O
a    O
blood    B-Assay100791527
film    I-Assay100791527
;    O

Cytochalasin    O
has    O
found    O
practical    O
application    O
in    O
thromboelastometry    B-Assay100791527
(    O
TEM    O
)    O
whole    O
blood    O
assays    O
for    O
the    O
assessment    O
of    O
fibrinogen    O
and    O
fibrin    O
polymerization    O
disorders    O
in    O
the    O
FIBTEM    O
assay    O
on    O
ROTEM    O
.    O

|    O
Procalcitonin    B-Assay100791527

Patients    O
will    O
also    O
most    O
likely    O
receive    O
a    O
complete    O
blood    O
count    O
(    O
or    O
full    O
blood    O
count    O
in    O
the    O
U.K.    O
)    O
,    O
looking    O
for    O
characteristic    O
findings    O
such    O
as    O
neutrophilia    B-Assay100791527
in    O
appendicitis    O
.    O

Neutrophilia    B-Assay100791527
,    O
or    O
an    O
increase    O
in    O
the    O
percentage    O
of    O
neutrophils    O
in    O
the    O
serum    O
white    O
blood    O
cell    O
count    O
.    O

It    O
is    O
believed    O
,    O
at    O
least    O
from    O
rodent    O
models    O
,    O
that    O
the    O
toxin    O
activates    O
a    O
series    O
of    O
receptors    O
promoting    O
macrophage    O
proliferation    O
,    O
inducing    O
neutrophilia    B-Assay100791527
and    O
leading    O
to    O
a    O
generalised    O
inflammatory    O
response    O
in    O
the    O
skin    O
.    O

Fingerstick    B-Assay100791527

Measuring    O
a    O
person    O
's    O
blood    O
lead    O
level    O
requires    O
a    O
blood    O
sample    O
,    O
which    O
may    O
be    O
performed    O
with    O
a    O
fingerstick    B-Assay100791527
or    O
a    O
blood    O
draw    O
.    O

Glycogen    B-Assay100791527
phosphorylase    I-Assay100791527
isoenzyme    I-Assay100791527
BB    I-Assay100791527
(    O
abbreviation    O
:    O
GPBB    B-Assay100791527
)    O
is    O
an    O
isoenzyme    O
of    O
glycogen    O
phosphorylase    O
.    O

Red    O
blood    O
cells    O
may    O
show    O
abnormalities    O
including    O
bizarre    B-Assay100791527
shapes    I-Assay100791527
,    O
such    O
as    O
teardrop-shaped    B-Assay100791527
cells    I-Assay100791527
,    O
and    O
nucleated    O
red    O
blood    O
cell    O
precursors    O
may    O
appear    O
in    O
the    O
blood    O
smear    O
.    O

An    O
example    O
of    O
a    O
provocation    O
test    O
,    O
performed    O
on    O
an    O
individual    O
,    O
is    O
a    O
skin    B-Assay100791527
allergy    I-Assay100791527
test    I-Assay100791527
.    O

However    O
,    O
more    O
conventional    O
allergy    O
testing    O
such    O
as    O
skin-prick    B-Assay100791527
tests    I-Assay100791527
can    O
provide    O
rapid    O
results    O
,    O
are    O
easy    O
to    O
conduct    O
and    O
inexpensive    O
,    O
though    O
they    O
may    O
indicate    O
false    O
-    O
positive    O
or    O
false    O
-    O
negative    O
results    O
.    O

The    O
protein    O
nitrogen    O
unit    O
(    O
PNU    O
)    O
measures    O
the    O
potency    O
of    O
the    O
compounds    O
used    O
in    O
allergy    B-Assay100791527
skin    I-Assay100791527
test    I-Assay100791527
,    O
and    O
is    O
equivalent    O
to    O
0.01    O
microgram    O
(    O
µg    O
)    O
of    O
phosphotungstic    O
acid    O
-    O
precipitable    O
protein    O
nitrogen    O
.    O

Hycor    O
Biomedical    O
mainly    O
produces    O
tests    O
and    O
equipment    O
relating    O
to    O
Allergy    B-Assay100791527
and    O
Autoimmune    O
Disease    O
.    O

Currently    O
,    O
Hycor    O
Biomedical    O
has    O
an    O
estimated    O
14%    O
market    O
share    O
in    O
allergy    B-Assay100791527
testing    I-Assay100791527
,    O
second    O
to    O
Thermo    O
Fisher    O
Scientific    O
's    O
Phadia    O
.    O

The    O
most    O
common    O
method    O
for    O
allergy    O
testing    O
is    O
through    O
skin    B-Assay100791527
prick    I-Assay100791527
testing    I-Assay100791527
.    O

Other    O
:    O
TCT    B-Assay100791527
,    O
bleeding    B-Assay100791527
time    I-Assay100791527
,    O
mixing    B-Assay100791527
test    I-Assay100791527
(    O
whether    O
an    O
abnormality    O
corrects    O
if    O
the    O
patient    O
's    O
plasma    O
is    O
mixed    O
with    O
normal    O
plasma    O
)    O
,    O
coagulation    O
factor    O
assays    O
,    O
antiphospholipid    O
antibodies    O
,    O
D-dimer    B-Assay100791527
,    O
genetic    O
tests    O
(    O
e.g.    O
factor    O
V    O
Leiden    O
,    O
prothrombin    O
mutation    O
G20210A    O
)    O
,    O
dilute    B-Assay100791527
Russell's    I-Assay100791527
viper    I-Assay100791527
venom    I-Assay100791527
time    I-Assay100791527
(    O
dRVVT    O
)    O
,    O
miscellaneous    O
platelet    O
function    O
tests    O
,    O
thromboelastography    B-Assay100791527
(    O
TEG    O
or    O
Sonoclot    O
)    O
,    O
euglobulin    B-Assay100791527
lysis    I-Assay100791527
time    I-Assay100791527
(    O
ELT    O
)    O
.    O

Thrombodynamics    B-Assay100791527
test    I-Assay100791527

|rowspan=2|    O
Total    B-Assay100791527
iron-binding    I-Assay100791527
capacity    I-Assay100791527
(    O
TIBC    O
)    O

The    O
total    B-Assay100791527
iron-binding    I-Assay100791527
capacity    I-Assay100791527
of    O
the    O
cells    O
is    O
normal    O
to    O
decreased    O
.    O

Normal    O
total    B-Assay100791527
iron-binding    I-Assay100791527
capacity    I-Assay100791527

Ecarin    O
is    O
an    O
enzyme    O
that    O
is    O
derived    O
from    O
the    O
venom    O
of    O
the    O
Indian    O
saw    O
-    O
scaled    O
viper    O
,    O
"    O
Echis    O
carinatus    O
"    O
,    O
It    O
is    O
the    O
primary    O
reagent    O
in    O
the    O
Ecarin    B-Assay100791527
clotting    I-Assay100791527
time    I-Assay100791527
test    O
.    O

Possible    O
non    O
-    O
specific    O
laboratory    O
indicators    O
of    O
EVD    O
include    O
a    O
low    O
platelet    O
count    O
;    O
an    O
initially    O
decreased    O
white    O
blood    O
cell    O
count    O
followed    O
by    O
an    O
increased    O
white    O
blood    O
cell    O
count    O
;    O
elevated    O
levels    O
of    O
the    O
liver    O
enzymes    O
alanine    O
aminotransferase    O
(    O
ALT    O
)    O
and    O
aspartate    O
aminotransferase    O
(    O
AST    O
)    O
;    O
and    O
abnormalities    O
in    O
blood    O
clotting    O
often    O
consistent    O
with    O
disseminated    O
intravascular    O
coagulation    O
(    O
DIC    O
)    O
such    O
as    O
a    O
prolonged    O
prothrombin    B-Assay100791527
time    I-Assay100791527
,    O
partial    B-Assay100791527
thromboplastin    I-Assay100791527
time    I-Assay100791527
,    O
and    O
bleeding    B-Assay100791527
time    I-Assay100791527
.    O

|    O
Bleeding    B-Assay100791527
time    I-Assay100791527

Abnormalities    O
of    O
the    O
GPIb    O
-    O
V    O
-    O
IX    O
complex    O
result    O
in    O
abnormal    O
appearance    O
and    O
functioning    O
of    O
platelets    O
resulting    O
in    O
Bernard    O
-    O
Soulier    O
syndrome    O
(    O
BSS    O
)    O
,    O
a    O
condition    O
first    O
described    O
by    O
Bernard    O
J    O
and    O
Soulier    O
J.P.    O
It    O
is    O
a    O
rare    O
hereditary    O
bleeding    O
disorder    O
most    O
commonly    O
with    O
an    O
autosomal    O
recessive    O
inheritance    O
and    O
diagnosed    O
based    O
on    O
prolonged    O
skin-bleeding    B-Assay100791527
time    I-Assay100791527
,    O
a    O
reduced    O
number    O
of    O
very    O
large    O
platelets    O
(    O
macrothrombocytopenia    O
)    O
and    O
defective    O
ristocetin    O
-    O
induced    O
platelet    O
agglutination    O
.    O

Anemia    O
of    O
chronic    O
disease    O
shows    O
unremarkable    O
RBCs    O
,    O
iron    O
deficiency    O
shows    O
anisocytosis    B-Assay100791527
,    O
anisochromia    B-Assay100791527
and    O
elliptocytosis    O
,    O
and    O
thalessemias    O
demonstrate    O
target    B-Assay100791527
cells    I-Assay100791527
and    O
coarse    O
basophilic    O
stippling    O
.    O

Downey    O
test    O
or    O
Apt    B-Assay100791527
test    I-Assay100791527
,    O
is    O
a    O
medical    O
test    O
used    O
to    O
differentiate    O
fetal    O
or    O
neonatal    O
blood    O
from    O
maternal    O
blood    O
found    O
in    O
a    O
newborn    O
's    O
stool    O
or    O
vomitus    O
.    O

Schumm    B-Assay100791527
test    I-Assay100791527


